Nutrient chapter

High-Fructose Corn Syrup / HFCS

A corn-derived glucose-fructose sweetener mixture, not one molecule and not pure fructose. HFCS-42 and HFCS-55 are separate formulations. Component-only experiments do not establish an HFCS-specific effect or a unique risk relative to sucrose.

55 recorded mechanisms · 4 availability situations · 2 preserved sources. Draft and verified records are labeled separately.

Read recorded mechanisms Open recursive mind map

The mechanisms

What the sources say this nutrient does, one relationship at a time. Plain wording comes first; the technical statement follows.

HFCS-42 is a formulation with approximately 42% fructose in its saccharide composition.
High-Fructose Corn Syrup / HFCS → HFCS-42 source_derived_draftungraded
Experimental context and source evidence
dose
HFCS-42 and HFCS-55; no administered dose
duration
Composition reference accessed 2026-09-20
evidence_access
Official FDA composition page; not a primary experiment.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Official description of HFCS formulations
exposure_scope
HFCS identity
limitations
Percentages describe sweetener composition, not beverage volume. This source is not a primary metabolic experiment.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Official description of HFCS formulations
plain_language
HFCS-42 is a formulation with approximately 42% fructose in its saccharide composition.
primary_references
[fda-hfcs-composition] High Fructose Corn Syrup Questions and Answers (accessed 2026). https://www.fda.gov/food/food-additives-petitions/high-fructose-corn-syrup-questions-and-answers
route
Not an intervention
tissue
Ingredient chemistry
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 17–27
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Official description of HFCS formulations · source_derived_draft · unverified_draft
## hfcs-form42 HFCS-42 is a formulation with approximately 42% fructose in its saccharide composition. Model/species: Official description of HFCS formulations Tissue: Ingredient chemistry Exposure: HFCS-42 and HFCS-55; no administered dose Route: Not an intervention Duration: Composition reference accessed 2026-09-20 Exposure scope: HFCS identity Limits: Percentages describe sweetener composition, not beverage volume. This source is not a primary metabolic experiment. Reference: [fda-hfcs-composition] High Fructose Corn Syrup Questions and Answers (accessed 2026). https://www.fda.gov/food/food-additives-petitions/high-fructose-corn-syrup-questions-and-answers Access: Official FDA composition page; not a primary experiment.
Complete structured claim and evidence
HFCS-55 is a formulation with approximately 55% fructose in its saccharide composition.
High-Fructose Corn Syrup / HFCS → HFCS-55 source_derived_draftungraded
Experimental context and source evidence
dose
HFCS-42 and HFCS-55; no administered dose
duration
Composition reference accessed 2026-09-20
evidence_access
Official FDA composition page; not a primary experiment.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Official description of HFCS formulations
exposure_scope
HFCS identity
limitations
Percentages describe sweetener composition, not beverage volume. This source is not a primary metabolic experiment.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Official description of HFCS formulations
plain_language
HFCS-55 is a formulation with approximately 55% fructose in its saccharide composition.
primary_references
[fda-hfcs-composition] High Fructose Corn Syrup Questions and Answers (accessed 2026). https://www.fda.gov/food/food-additives-petitions/high-fructose-corn-syrup-questions-and-answers
route
Not an intervention
tissue
Ingredient chemistry
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 29–39
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Official description of HFCS formulations · source_derived_draft · unverified_draft
## hfcs-form55 HFCS-55 is a formulation with approximately 55% fructose in its saccharide composition. Model/species: Official description of HFCS formulations Tissue: Ingredient chemistry Exposure: HFCS-42 and HFCS-55; no administered dose Route: Not an intervention Duration: Composition reference accessed 2026-09-20 Exposure scope: HFCS identity Limits: Percentages describe sweetener composition, not beverage volume. This source is not a primary metabolic experiment. Reference: [fda-hfcs-composition] High Fructose Corn Syrup Questions and Answers (accessed 2026). https://www.fda.gov/food/food-additives-petitions/high-fructose-corn-syrup-questions-and-answers Access: Official FDA composition page; not a primary experiment.
Complete structured claim and evidence
HFCS contains free fructose rather than fructose linked to glucose in sucrose.
High-Fructose Corn Syrup / HFCS → Fructose source_derived_draftungraded
Experimental context and source evidence
dose
HFCS-42 and HFCS-55; no administered dose
duration
Composition reference accessed 2026-09-20
evidence_access
Official FDA composition page; not a primary experiment.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Official description of HFCS formulations
exposure_scope
HFCS identity
limitations
Percentages describe sweetener composition, not beverage volume. This source is not a primary metabolic experiment.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Official description of HFCS formulations
plain_language
HFCS contains free fructose rather than fructose linked to glucose in sucrose.
primary_references
[fda-hfcs-composition] High Fructose Corn Syrup Questions and Answers (accessed 2026). https://www.fda.gov/food/food-additives-petitions/high-fructose-corn-syrup-questions-and-answers
route
Not an intervention
tissue
Ingredient chemistry
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 41–51
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Official description of HFCS formulations · source_derived_draft · unverified_draft
## hfcs-fructose-component HFCS contains free fructose rather than fructose linked to glucose in sucrose. Model/species: Official description of HFCS formulations Tissue: Ingredient chemistry Exposure: HFCS-42 and HFCS-55; no administered dose Route: Not an intervention Duration: Composition reference accessed 2026-09-20 Exposure scope: HFCS identity Limits: Percentages describe sweetener composition, not beverage volume. This source is not a primary metabolic experiment. Reference: [fda-hfcs-composition] High Fructose Corn Syrup Questions and Answers (accessed 2026). https://www.fda.gov/food/food-additives-petitions/high-fructose-corn-syrup-questions-and-answers Access: Official FDA composition page; not a primary experiment.
Complete structured claim and evidence
HFCS contains free glucose alongside fructose.
High-Fructose Corn Syrup / HFCS → D-glucose source_derived_draftungraded
Experimental context and source evidence
dose
HFCS-42 and HFCS-55; no administered dose
duration
Composition reference accessed 2026-09-20
evidence_access
Official FDA composition page; not a primary experiment.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Official description of HFCS formulations
exposure_scope
HFCS identity
limitations
Percentages describe sweetener composition, not beverage volume. This source is not a primary metabolic experiment.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Official description of HFCS formulations
plain_language
HFCS contains free glucose alongside fructose.
primary_references
[fda-hfcs-composition] High Fructose Corn Syrup Questions and Answers (accessed 2026). https://www.fda.gov/food/food-additives-petitions/high-fructose-corn-syrup-questions-and-answers
route
Not an intervention
tissue
Ingredient chemistry
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 53–63
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Official description of HFCS formulations · source_derived_draft · unverified_draft
## hfcs-glucose-component HFCS contains free glucose alongside fructose. Model/species: Official description of HFCS formulations Tissue: Ingredient chemistry Exposure: HFCS-42 and HFCS-55; no administered dose Route: Not an intervention Duration: Composition reference accessed 2026-09-20 Exposure scope: HFCS identity Limits: Percentages describe sweetener composition, not beverage volume. This source is not a primary metabolic experiment. Reference: [fda-hfcs-composition] High Fructose Corn Syrup Questions and Answers (accessed 2026). https://www.fda.gov/food/food-additives-petitions/high-fructose-corn-syrup-questions-and-answers Access: Official FDA composition page; not a primary experiment.
Complete structured claim and evidence
Expressed human GLUT5 selectively transported fructose, with a reported Km near 6 mM.
Human fructose transporter GLUT5 / SLC2A5 → Fructose source_derived_draftungraded
Experimental context and source evidence
dose
Fructose kinetic series; reported Km about 6 mM
duration
Assay interval unavailable in abstract
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Human GLUT5 expressed in Xenopus oocytes
exposure_scope
Isolated fructose / human protein
limitations
Human protein in an amphibian expression system; not a measured human intake threshold.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Human GLUT5 expressed in Xenopus oocytes
plain_language
Expressed human GLUT5 selectively transported fructose, with a reported Km near 6 mM.
primary_references
Fructose transporter in human spermatozoa and small intestine is GLUT5. (1992). https://pubmed.ncbi.nlm.nih.gov/1634504/
route
In vitro substrate addition
tissue
Recombinant transport assay
transport_effect
raises Fructose uptake measured in the expressing cell with a reported Km near 6 mM.
transport_pool
the expressing cell Fructose uptake measured in the expressing cell with a reported Km near 6 mM.
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 65–75
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Human GLUT5 expressed in Xenopus oocytes · source_derived_draft · unverified_draft
## hfcs-glut5 Expressed human GLUT5 selectively transported fructose, with a reported Km near 6 mM. Model/species: Human GLUT5 expressed in Xenopus oocytes Tissue: Recombinant transport assay Exposure: Fructose kinetic series; reported Km about 6 mM Route: In vitro substrate addition Duration: Assay interval unavailable in abstract Exposure scope: Isolated fructose / human protein Limits: Human protein in an amphibian expression system; not a measured human intake threshold. Reference: Fructose transporter in human spermatozoa and small intestine is GLUT5. (1992). https://pubmed.ncbi.nlm.nih.gov/1634504/ Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Adding 50 g glucose to 50 g fructose eliminated detectable breath-test malabsorption in all ten volunteers, compared with eight positive tests after fructose alone.
D-glucose → Human fructose malabsorption assessed by hydrogen breath testing source_derived_draftungraded
Experimental context and source evidence
dose
50 g fructose alone or with 12.5, 25 or 50 g glucose; 10% fructose solutions
duration
Breath sampling over 3-4 h
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Ten healthy adult volunteers
exposure_scope
Component sugar mixtures, not a commercial HFCS product
limitations
Small physiological study; breath hydrogen is an indirect absorption readout and symptoms were mild or absent. No specific transporter mechanism was proven by adding glucose.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Ten healthy adult volunteers
plain_language
Adding 50 g glucose to 50 g fructose eliminated detectable breath-test malabsorption in all ten volunteers, compared with eight positive tests after fructose alone.
primary_references
Absorption capacity of fructose in healthy adults. Comparison with sucrose and its constituent monosaccharides. (1986). https://pubmed.ncbi.nlm.nih.gov/3781328/ DOI: 10.1136/gut.27.10.1161
route
Oral sugar challenges
tissue
Hydrogen breath tests
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 77–87
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Ten healthy adult volunteers · source_derived_draft · unverified_draft
## hfcs-glucose-absorption Adding 50 g glucose to 50 g fructose eliminated detectable breath-test malabsorption in all ten volunteers, compared with eight positive tests after fructose alone. Model/species: Ten healthy adult volunteers Tissue: Hydrogen breath tests Exposure: 50 g fructose alone or with 12.5, 25 or 50 g glucose; 10% fructose solutions Route: Oral sugar challenges Duration: Breath sampling over 3-4 h Exposure scope: Component sugar mixtures, not a commercial HFCS product Limits: Small physiological study; breath hydrogen is an indirect absorption readout and symptoms were mild or absent. No specific transporter mechanism was proven by adding glucose. Reference: Absorption capacity of fructose in healthy adults. Comparison with sucrose and its constituent monosaccharides. (1986). https://pubmed.ncbi.nlm.nih.gov/3781328/ DOI: 10.1136/gut.27.10.1161 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Fructose alone exceeded measured absorption capacity at different doses across the ten healthy volunteers.
Fructose → Human fructose malabsorption assessed by hydrogen breath testing source_derived_draftungraded
Experimental context and source evidence
dose
50 g fructose alone or with 12.5, 25 or 50 g glucose; 10% fructose solutions
duration
Breath sampling over 3-4 h
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Ten healthy adult volunteers
exposure_scope
Component sugar mixtures, not a commercial HFCS product
limitations
Small physiological study; breath hydrogen is an indirect absorption readout and symptoms were mild or absent. No specific transporter mechanism was proven by adding glucose.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Ten healthy adult volunteers
plain_language
Fructose alone exceeded measured absorption capacity at different doses across the ten healthy volunteers.
primary_references
Absorption capacity of fructose in healthy adults. Comparison with sucrose and its constituent monosaccharides. (1986). https://pubmed.ncbi.nlm.nih.gov/3781328/ DOI: 10.1136/gut.27.10.1161
route
Oral sugar challenges
tissue
Hydrogen breath tests
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 89–99
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Ten healthy adult volunteers · source_derived_draft · unverified_draft
## hfcs-fructose-malabsorption Fructose alone exceeded measured absorption capacity at different doses across the ten healthy volunteers. Model/species: Ten healthy adult volunteers Tissue: Hydrogen breath tests Exposure: 50 g fructose alone or with 12.5, 25 or 50 g glucose; 10% fructose solutions Route: Oral sugar challenges Duration: Breath sampling over 3-4 h Exposure scope: Component sugar mixtures, not a commercial HFCS product Limits: Small physiological study; breath hydrogen is an indirect absorption readout and symptoms were mild or absent. No specific transporter mechanism was proven by adding glucose. Reference: Absorption capacity of fructose in healthy adults. Comparison with sucrose and its constituent monosaccharides. (1986). https://pubmed.ncbi.nlm.nih.gov/3781328/ DOI: 10.1136/gut.27.10.1161 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Purified human liver ketohexokinase catalyzed the ATP-dependent phosphorylation of fructose.
Human ketohexokinase / KHK → D-Fructose 1-phosphate source_derived_draftungraded
Experimental context and source evidence
dose
Fructose substrate and ATP-dependent enzyme characterization; exact concentrations not in abstract
duration
Assay duration not recovered
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Ketohexokinase purified from human liver
exposure_scope
Human component biochemistry
limitations
Isoform unresolved; enzyme chemistry does not quantify whole-body flux after ordinary HFCS intake. Only abstract/metadata recovered for this scanned article.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Ketohexokinase purified from human liver
plain_language
Purified human liver ketohexokinase catalyzed the ATP-dependent phosphorylation of fructose.
primary_references
The purification and properties of human liver ketohexokinase. A role for ketohexokinase and fructose-bisphosphate aldolase in the metabolic production of oxalate from xylitol. (1985). https://pubmed.ncbi.nlm.nih.gov/2996495/ DOI: 10.1042/bj2300053
route
In vitro enzyme/substrate incubation
tissue
Cell-free enzyme kinetics
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 101–111
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Ketohexokinase purified from human liver · source_derived_draft · unverified_draft
## hfcs-khk-phosphorylation Purified human liver ketohexokinase catalyzed the ATP-dependent phosphorylation of fructose. Model/species: Ketohexokinase purified from human liver Tissue: Cell-free enzyme kinetics Exposure: Fructose substrate and ATP-dependent enzyme characterization; exact concentrations not in abstract Route: In vitro enzyme/substrate incubation Duration: Assay duration not recovered Exposure scope: Human component biochemistry Limits: Isoform unresolved; enzyme chemistry does not quantify whole-body flux after ordinary HFCS intake. Only abstract/metadata recovered for this scanned article. Reference: The purification and properties of human liver ketohexokinase. A role for ketohexokinase and fructose-bisphosphate aldolase in the metabolic production of oxalate from xylitol. (1985). https://pubmed.ncbi.nlm.nih.gov/2996495/ DOI: 10.1042/bj2300053 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Wild-type recombinant human aldolase B had catalytic activity toward fructose 1-phosphate.
Human aldolase B / ALDOB → D-Fructose 1-phosphate source_derived_draftungraded
Experimental context and source evidence
dose
Wild-type versus hereditary-fructose-intolerance-associated variants; exact substrate series not in abstract
duration
Assay duration not recovered
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Recombinant wild-type and Arg303Trp human ALDOB
exposure_scope
Human genetic machinery / fructose component
limitations
A mutation-specific activity defect is not ordinary dietary intolerance or a population toxicity threshold. Full article is scanned; abstract kinetics used.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Recombinant wild-type and Arg303Trp human ALDOB
plain_language
Wild-type recombinant human aldolase B had catalytic activity toward fructose 1-phosphate.
primary_references
Functional and molecular modelling studies of two hereditary fructose intolerance-causing mutations at arginine 303 in human liver aldolase. (2000). https://pubmed.ncbi.nlm.nih.gov/10970798/
route
In vitro recombinant enzyme assay
tissue
Fructose-1-phosphate enzyme assay
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 113–123
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Recombinant wild-type and Arg303Trp human ALDOB · source_derived_draft · unverified_draft
## hfcs-aldob-activity Wild-type recombinant human aldolase B had catalytic activity toward fructose 1-phosphate. Model/species: Recombinant wild-type and Arg303Trp human ALDOB Tissue: Fructose-1-phosphate enzyme assay Exposure: Wild-type versus hereditary-fructose-intolerance-associated variants; exact substrate series not in abstract Route: In vitro recombinant enzyme assay Duration: Assay duration not recovered Exposure scope: Human genetic machinery / fructose component Limits: A mutation-specific activity defect is not ordinary dietary intolerance or a population toxicity threshold. Full article is scanned; abstract kinetics used. Reference: Functional and molecular modelling studies of two hereditary fructose intolerance-causing mutations at arginine 303 in human liver aldolase. (2000). https://pubmed.ncbi.nlm.nih.gov/10970798/ Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
The human ALDOB Arg303Trp variant had no detectable fructose-1-phosphate activity in the reported assay.
Human ALDOB Arg303Trp variant → D-Fructose 1-phosphate source_derived_draftungraded
Experimental context and source evidence
availability_state
machinery_impairment Imported condition classification; unverified.
dose
Wild-type versus hereditary-fructose-intolerance-associated variants; exact substrate series not in abstract
duration
Assay duration not recovered
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Recombinant wild-type and Arg303Trp human ALDOB
exposure_scope
Human genetic machinery / fructose component
limitations
A mutation-specific activity defect is not ordinary dietary intolerance or a population toxicity threshold. Full article is scanned; abstract kinetics used.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Recombinant wild-type and Arg303Trp human ALDOB
plain_language
The human ALDOB Arg303Trp variant had no detectable fructose-1-phosphate activity in the reported assay.
primary_references
Functional and molecular modelling studies of two hereditary fructose intolerance-causing mutations at arginine 303 in human liver aldolase. (2000). https://pubmed.ncbi.nlm.nih.gov/10970798/
route
In vitro recombinant enzyme assay
tissue
Fructose-1-phosphate enzyme assay
trigger_kind
machinery_impairment Imported condition classification; unverified.
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 125–135
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Recombinant wild-type and Arg303Trp human ALDOB · source_derived_draft · unverified_draft
## hfcs-aldob-variant The human ALDOB Arg303Trp variant had no detectable fructose-1-phosphate activity in the reported assay. Model/species: Recombinant wild-type and Arg303Trp human ALDOB Tissue: Fructose-1-phosphate enzyme assay Exposure: Wild-type versus hereditary-fructose-intolerance-associated variants; exact substrate series not in abstract Route: In vitro recombinant enzyme assay Duration: Assay duration not recovered Exposure scope: Human genetic machinery / fructose component Limits: A mutation-specific activity defect is not ordinary dietary intolerance or a population toxicity threshold. Full article is scanned; abstract kinetics used. Reference: Functional and molecular modelling studies of two hereditary fructose intolerance-causing mutations at arginine 303 in human liver aldolase. (2000). https://pubmed.ncbi.nlm.nih.gov/10970798/ Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Low-dose oral fructose was approximately 90% cleared by the small intestine in the mouse tracer experiment.
Fructose → Mouse small-intestinal fructose clearance source_derived_draftungraded
Experimental context and source evidence
dose
1:1 fructose/glucose gavage, typically 0.5 g/kg each; dose series 0.25-2 g/kg each
duration
Acute tracing; knockout portal AUC 0-30 min
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Male C57BL/6 mice, with Khk knockout comparisons
exposure_scope
Component mixture
limitations
Approximately 90% low-dose clearance is a mouse result, not an established human percentage. Fasting, feeding and prior exposure change clearance.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Male C57BL/6 mice, with Khk knockout comparisons
plain_language
Low-dose oral fructose was approximately 90% cleared by the small intestine in the mouse tracer experiment.
primary_references
The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. (2018). https://pubmed.ncbi.nlm.nih.gov/29414685/ DOI: 10.1016/j.cmet.2017.12.016
route
Oral gavage with isotope tracers
tissue
Small intestine, portal blood and liver
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 137–147
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Male C57BL/6 mice, with Khk knockout comparisons · source_derived_draft · unverified_draft
## hfcs-intestinal-clearance Low-dose oral fructose was approximately 90% cleared by the small intestine in the mouse tracer experiment. Model/species: Male C57BL/6 mice, with Khk knockout comparisons Tissue: Small intestine, portal blood and liver Exposure: 1:1 fructose/glucose gavage, typically 0.5 g/kg each; dose series 0.25-2 g/kg each Route: Oral gavage with isotope tracers Duration: Acute tracing; knockout portal AUC 0-30 min Exposure scope: Component mixture Limits: Approximately 90% low-dose clearance is a mouse result, not an established human percentage. Fasting, feeding and prior exposure change clearance. Reference: The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. (2018). https://pubmed.ncbi.nlm.nih.gov/29414685/ DOI: 10.1016/j.cmet.2017.12.016 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Mouse intestinal tracing detected fructose-derived glucose in portal blood.
Fructose → D-glucose source_derived_draftungraded
Experimental context and source evidence
dose
1:1 fructose/glucose gavage, typically 0.5 g/kg each; dose series 0.25-2 g/kg each
duration
Acute tracing; knockout portal AUC 0-30 min
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Male C57BL/6 mice, with Khk knockout comparisons
exposure_scope
Component mixture
limitations
Approximately 90% low-dose clearance is a mouse result, not an established human percentage. Fasting, feeding and prior exposure change clearance.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Male C57BL/6 mice, with Khk knockout comparisons
plain_language
Mouse intestinal tracing detected fructose-derived glucose in portal blood.
primary_references
The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. (2018). https://pubmed.ncbi.nlm.nih.gov/29414685/ DOI: 10.1016/j.cmet.2017.12.016
route
Oral gavage with isotope tracers
tissue
Small intestine, portal blood and liver
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 149–159
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Male C57BL/6 mice, with Khk knockout comparisons · source_derived_draft · unverified_draft
## hfcs-intestinal-glucose Mouse intestinal tracing detected fructose-derived glucose in portal blood. Model/species: Male C57BL/6 mice, with Khk knockout comparisons Tissue: Small intestine, portal blood and liver Exposure: 1:1 fructose/glucose gavage, typically 0.5 g/kg each; dose series 0.25-2 g/kg each Route: Oral gavage with isotope tracers Duration: Acute tracing; knockout portal AUC 0-30 min Exposure scope: Component mixture Limits: Approximately 90% low-dose clearance is a mouse result, not an established human percentage. Fasting, feeding and prior exposure change clearance. Reference: The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. (2018). https://pubmed.ncbi.nlm.nih.gov/29414685/ DOI: 10.1016/j.cmet.2017.12.016 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Mouse intestinal tracing detected fructose-derived lactate in portal blood.
Fructose → L-Lactate source_derived_draftungraded
Experimental context and source evidence
dose
1:1 fructose/glucose gavage, typically 0.5 g/kg each; dose series 0.25-2 g/kg each
duration
Acute tracing; knockout portal AUC 0-30 min
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Male C57BL/6 mice, with Khk knockout comparisons
exposure_scope
Component mixture
limitations
Approximately 90% low-dose clearance is a mouse result, not an established human percentage. Fasting, feeding and prior exposure change clearance.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Male C57BL/6 mice, with Khk knockout comparisons
plain_language
Mouse intestinal tracing detected fructose-derived lactate in portal blood.
primary_references
The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. (2018). https://pubmed.ncbi.nlm.nih.gov/29414685/ DOI: 10.1016/j.cmet.2017.12.016
route
Oral gavage with isotope tracers
tissue
Small intestine, portal blood and liver
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 161–171
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Male C57BL/6 mice, with Khk knockout comparisons · source_derived_draft · unverified_draft
## hfcs-intestinal-lactate Mouse intestinal tracing detected fructose-derived lactate in portal blood. Model/species: Male C57BL/6 mice, with Khk knockout comparisons Tissue: Small intestine, portal blood and liver Exposure: 1:1 fructose/glucose gavage, typically 0.5 g/kg each; dose series 0.25-2 g/kg each Route: Oral gavage with isotope tracers Duration: Acute tracing; knockout portal AUC 0-30 min Exposure scope: Component mixture Limits: Approximately 90% low-dose clearance is a mouse result, not an established human percentage. Fasting, feeding and prior exposure change clearance. Reference: The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. (2018). https://pubmed.ncbi.nlm.nih.gov/29414685/ DOI: 10.1016/j.cmet.2017.12.016 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
At higher gavage doses, intestinal processing saturated and more intact fructose reached mouse portal blood and the liver.
Fructose → Mouse portal delivery of intact fructose source_derived_draftungraded
Experimental context and source evidence
dose
1:1 fructose/glucose gavage, typically 0.5 g/kg each; dose series 0.25-2 g/kg each
duration
Acute tracing; knockout portal AUC 0-30 min
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Male C57BL/6 mice, with Khk knockout comparisons
exposure_scope
Component mixture
limitations
Approximately 90% low-dose clearance is a mouse result, not an established human percentage. Fasting, feeding and prior exposure change clearance.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Male C57BL/6 mice, with Khk knockout comparisons
plain_language
At higher gavage doses, intestinal processing saturated and more intact fructose reached mouse portal blood and the liver.
primary_references
The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. (2018). https://pubmed.ncbi.nlm.nih.gov/29414685/ DOI: 10.1016/j.cmet.2017.12.016
route
Oral gavage with isotope tracers
tissue
Small intestine, portal blood and liver
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 173–183
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Male C57BL/6 mice, with Khk knockout comparisons · source_derived_draft · unverified_draft
## hfcs-intestinal-overflow At higher gavage doses, intestinal processing saturated and more intact fructose reached mouse portal blood and the liver. Model/species: Male C57BL/6 mice, with Khk knockout comparisons Tissue: Small intestine, portal blood and liver Exposure: 1:1 fructose/glucose gavage, typically 0.5 g/kg each; dose series 0.25-2 g/kg each Route: Oral gavage with isotope tracers Duration: Acute tracing; knockout portal AUC 0-30 min Exposure scope: Component mixture Limits: Approximately 90% low-dose clearance is a mouse result, not an established human percentage. Fasting, feeding and prior exposure change clearance. Reference: The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids. (2018). https://pubmed.ncbi.nlm.nih.gov/29414685/ DOI: 10.1016/j.cmet.2017.12.016 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Deleting intestinal Khk-C increased fructose spillover and hepatic lipogenesis during sucrose feeding in mice.
Mouse ketohexokinase C isoform / Khk-C → Mouse hepatic de novo lipogenesis source_derived_draftungraded
Experimental context and source evidence
availability_state
machinery_impairment Imported condition classification; unverified.
dose
10% sucrose in drinking water
duration
8 weeks
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Intestine-specific Khk-C knockout mice and littermate controls
exposure_scope
Sucrose / fructose-component mechanism
limitations
Tissue-specific deletion differs from systemic KHK inhibition. Source is sucrose exposure, not an HFCS trial; mouse intake patterns are not a human safety threshold.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Intestine-specific Khk-C knockout mice and littermate controls
plain_language
Deleting intestinal Khk-C increased fructose spillover and hepatic lipogenesis during sucrose feeding in mice.
primary_references
The small intestine shields the liver from fructose-induced steatosis. (2020). https://pubmed.ncbi.nlm.nih.gov/32694791/ DOI: 10.1038/s42255-020-0222-9
route
Oral ad libitum sucrose with genetic deletion
tissue
Intestinal clearance and liver lipid metabolism
trigger_kind
machinery_impairment Imported condition classification; unverified.
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 185–195
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Intestine-specific Khk-C knockout mice and littermate controls · source_derived_draft · unverified_draft
## hfcs-intestinal-khk-deletion Deleting intestinal Khk-C increased fructose spillover and hepatic lipogenesis during sucrose feeding in mice. Model/species: Intestine-specific Khk-C knockout mice and littermate controls Tissue: Intestinal clearance and liver lipid metabolism Exposure: 10% sucrose in drinking water Route: Oral ad libitum sucrose with genetic deletion Duration: 8 weeks Exposure scope: Sucrose / fructose-component mechanism Limits: Tissue-specific deletion differs from systemic KHK inhibition. Source is sucrose exposure, not an HFCS trial; mouse intake patterns are not a human safety threshold. Reference: The small intestine shields the liver from fructose-induced steatosis. (2020). https://pubmed.ncbi.nlm.nih.gov/32694791/ DOI: 10.1038/s42255-020-0222-9 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Dividing the same fructose dose over 45 minutes reduced hepatic lipogenesis relative to a single mouse gavage bolus.
Fructose → Mouse hepatic de novo lipogenesis source_derived_draftungraded
Experimental context and source evidence
dose
2 g/kg fructose plus matched glucose once versus four 0.5 g/kg fructose doses 15 min apart
duration
Equal total dose delivered over 45 min versus one bolus
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Tracer experiments in mice
exposure_scope
Component mixture
limitations
Same sugar amount with different delivery rates; does not quantify a recommended human rate.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Tracer experiments in mice
plain_language
Dividing the same fructose dose over 45 minutes reduced hepatic lipogenesis relative to a single mouse gavage bolus.
primary_references
The small intestine shields the liver from fructose-induced steatosis. (2020). https://pubmed.ncbi.nlm.nih.gov/32694791/ DOI: 10.1038/s42255-020-0222-9
route
Oral gavage
tissue
Intestinal processing and hepatic lipogenesis
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 197–207
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Tracer experiments in mice · source_derived_draft · unverified_draft
## hfcs-delivery-rate Dividing the same fructose dose over 45 minutes reduced hepatic lipogenesis relative to a single mouse gavage bolus. Model/species: Tracer experiments in mice Tissue: Intestinal processing and hepatic lipogenesis Exposure: 2 g/kg fructose plus matched glucose once versus four 0.5 g/kg fructose doses 15 min apart Route: Oral gavage Duration: Equal total dose delivered over 45 min versus one bolus Exposure scope: Component mixture Limits: Same sugar amount with different delivery rates; does not quantify a recommended human rate. Reference: The small intestine shields the liver from fructose-induced steatosis. (2020). https://pubmed.ncbi.nlm.nih.gov/32694791/ DOI: 10.1038/s42255-020-0222-9 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Mouse tracer experiments identified gut-microbial acetate derived from ingested fructose.
Fructose → Acetate source_derived_draftungraded
Experimental context and source evidence
dose
Bolus 2 g/kg labeled fructose plus 2 g/kg glucose; interventions specified by claim
duration
Acute isotope sampling up to 6 h
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Wild-type mice, microbiota depletion and liver Acss2-silencing experiments
exposure_scope
Component mixture
limitations
Carbon tracing supports microbial acetate supply; antibiotic depletion is not a clinical recommendation and microbiota effects are not universal across diets.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Wild-type mice, microbiota depletion and liver Acss2-silencing experiments
plain_language
Mouse tracer experiments identified gut-microbial acetate derived from ingested fructose.
primary_references
Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. (2020). https://pubmed.ncbi.nlm.nih.gov/32214246/ DOI: 10.1038/s41586-020-2101-7
route
Oral gavage and experimental microbiota/gene perturbation
tissue
Portal acetate and hepatic fatty-acid labeling
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 209–219
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Wild-type mice, microbiota depletion and liver Acss2-silencing experiments · source_derived_draft · unverified_draft
## hfcs-microbial-acetate Mouse tracer experiments identified gut-microbial acetate derived from ingested fructose. Model/species: Wild-type mice, microbiota depletion and liver Acss2-silencing experiments Tissue: Portal acetate and hepatic fatty-acid labeling Exposure: Bolus 2 g/kg labeled fructose plus 2 g/kg glucose; interventions specified by claim Route: Oral gavage and experimental microbiota/gene perturbation Duration: Acute isotope sampling up to 6 h Exposure scope: Component mixture Limits: Carbon tracing supports microbial acetate supply; antibiotic depletion is not a clinical recommendation and microbiota effects are not universal across diets. Reference: Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. (2020). https://pubmed.ncbi.nlm.nih.gov/32214246/ DOI: 10.1038/s41586-020-2101-7 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Silencing hepatic Acss2 suppressed conversion of bolus fructose carbon into hepatic acetyl-CoA and fatty acids in mice.
Mouse acyl-CoA synthetase short-chain family member 2 / Acss2 → Fructose-carbon incorporation into mouse hepatic fatty acids source_derived_draftungraded
Experimental context and source evidence
availability_state
machinery_impairment Imported condition classification; unverified.
dose
Bolus 2 g/kg labeled fructose plus 2 g/kg glucose; interventions specified by claim
duration
Acute isotope sampling up to 6 h
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Wild-type mice, microbiota depletion and liver Acss2-silencing experiments
exposure_scope
Component mixture
limitations
Carbon tracing supports microbial acetate supply; antibiotic depletion is not a clinical recommendation and microbiota effects are not universal across diets.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Wild-type mice, microbiota depletion and liver Acss2-silencing experiments
plain_language
Silencing hepatic Acss2 suppressed conversion of bolus fructose carbon into hepatic acetyl-CoA and fatty acids in mice.
primary_references
Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. (2020). https://pubmed.ncbi.nlm.nih.gov/32214246/ DOI: 10.1038/s41586-020-2101-7
route
Oral gavage and experimental microbiota/gene perturbation
tissue
Portal acetate and hepatic fatty-acid labeling
trigger_kind
machinery_impairment Imported condition classification; unverified.
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 221–231
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Wild-type mice, microbiota depletion and liver Acss2-silencing experiments · source_derived_draft · unverified_draft
## hfcs-acss2-silencing Silencing hepatic Acss2 suppressed conversion of bolus fructose carbon into hepatic acetyl-CoA and fatty acids in mice. Model/species: Wild-type mice, microbiota depletion and liver Acss2-silencing experiments Tissue: Portal acetate and hepatic fatty-acid labeling Exposure: Bolus 2 g/kg labeled fructose plus 2 g/kg glucose; interventions specified by claim Route: Oral gavage and experimental microbiota/gene perturbation Duration: Acute isotope sampling up to 6 h Exposure scope: Component mixture Limits: Carbon tracing supports microbial acetate supply; antibiotic depletion is not a clinical recommendation and microbiota effects are not universal across diets. Reference: Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. (2020). https://pubmed.ncbi.nlm.nih.gov/32214246/ DOI: 10.1038/s41586-020-2101-7 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Intravenous fructose acutely lowered hepatic ATP in seven healthy volunteers.
Fructose → Human hepatic ATP measured by phosphorus MRS source_derived_draftungraded
Experimental context and source evidence
dose
Fructose 250 mg/kg bolus
duration
Early 5 min changes; sugar-phosphate recovery within about 20 min
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Seven healthy human volunteers
exposure_scope
Isolated fructose, intravenous
limitations
Injection bypasses the intestine. Magnitude cannot be assigned to a normal oral HFCS serving or to dietary phosphate deficiency.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Seven healthy human volunteers
plain_language
Intravenous fructose acutely lowered hepatic ATP in seven healthy volunteers.
primary_references
Assessment of human liver metabolism by phosphorus-31 magnetic resonance spectroscopy. (1986). https://pubmed.ncbi.nlm.nih.gov/3730768/ DOI: 10.1259/0007-1285-59-703-695
route
Intravenous injection
tissue
Liver phosphorus-31 MRS
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 233–243
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Seven healthy human volunteers · source_derived_draft · unverified_draft
## hfcs-iv-atp Intravenous fructose acutely lowered hepatic ATP in seven healthy volunteers. Model/species: Seven healthy human volunteers Tissue: Liver phosphorus-31 MRS Exposure: Fructose 250 mg/kg bolus Route: Intravenous injection Duration: Early 5 min changes; sugar-phosphate recovery within about 20 min Exposure scope: Isolated fructose, intravenous Limits: Injection bypasses the intestine. Magnitude cannot be assigned to a normal oral HFCS serving or to dietary phosphate deficiency. Reference: Assessment of human liver metabolism by phosphorus-31 magnetic resonance spectroscopy. (1986). https://pubmed.ncbi.nlm.nih.gov/3730768/ DOI: 10.1259/0007-1285-59-703-695 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
The intravenous fructose bolus acutely lowered hepatic inorganic phosphate as sugar phosphates accumulated.
Fructose → Human hepatic inorganic phosphate measured by phosphorus MRS source_derived_draftungraded
Experimental context and source evidence
dose
Fructose 250 mg/kg bolus
duration
Early 5 min changes; sugar-phosphate recovery within about 20 min
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Seven healthy human volunteers
exposure_scope
Isolated fructose, intravenous
limitations
Injection bypasses the intestine. Magnitude cannot be assigned to a normal oral HFCS serving or to dietary phosphate deficiency.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Seven healthy human volunteers
plain_language
The intravenous fructose bolus acutely lowered hepatic inorganic phosphate as sugar phosphates accumulated.
primary_references
Assessment of human liver metabolism by phosphorus-31 magnetic resonance spectroscopy. (1986). https://pubmed.ncbi.nlm.nih.gov/3730768/ DOI: 10.1259/0007-1285-59-703-695
route
Intravenous injection
tissue
Liver phosphorus-31 MRS
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 245–255
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Seven healthy human volunteers · source_derived_draft · unverified_draft
## hfcs-iv-phosphate The intravenous fructose bolus acutely lowered hepatic inorganic phosphate as sugar phosphates accumulated. Model/species: Seven healthy human volunteers Tissue: Liver phosphorus-31 MRS Exposure: Fructose 250 mg/kg bolus Route: Intravenous injection Duration: Early 5 min changes; sugar-phosphate recovery within about 20 min Exposure scope: Isolated fructose, intravenous Limits: Injection bypasses the intestine. Magnitude cannot be assigned to a normal oral HFCS serving or to dietary phosphate deficiency. Reference: Assessment of human liver metabolism by phosphorus-31 magnetic resonance spectroscopy. (1986). https://pubmed.ncbi.nlm.nih.gov/3730768/ DOI: 10.1259/0007-1285-59-703-695 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
After 75 g oral fructose, hepatic ATP decreased within 15 minutes and remained lower at 60 minutes in participants without MASLD.
Fructose → Human hepatic ATP measured by phosphorus MRS source_derived_draftungraded
Experimental context and source evidence
dose
75 g fructose challenge
duration
60 min
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
37 overweight/obese adults without diabetes, stratified by MASLD
exposure_scope
Isolated fructose, oral
limitations
Small acute component study; the ATP response was blunted in MASLD, not uniformly greater. Metabolite signals are not chronic clinical outcomes.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
37 overweight/obese adults without diabetes, stratified by MASLD
plain_language
After 75 g oral fructose, hepatic ATP decreased within 15 minutes and remained lower at 60 minutes in participants without MASLD.
primary_references
Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption. (2026). https://pubmed.ncbi.nlm.nih.gov/41866318/ DOI: 10.1210/clinem/dgag125
route
Oral solution
tissue
Liver phosphorus-31 MRS
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 257–267
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 37 overweight/obese adults without diabetes, stratified by MASLD · source_derived_draft · unverified_draft
## hfcs-oral-atp After 75 g oral fructose, hepatic ATP decreased within 15 minutes and remained lower at 60 minutes in participants without MASLD. Model/species: 37 overweight/obese adults without diabetes, stratified by MASLD Tissue: Liver phosphorus-31 MRS Exposure: 75 g fructose challenge Route: Oral solution Duration: 60 min Exposure scope: Isolated fructose, oral Limits: Small acute component study; the ATP response was blunted in MASLD, not uniformly greater. Metabolite signals are not chronic clinical outcomes. Reference: Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption. (2026). https://pubmed.ncbi.nlm.nih.gov/41866318/ DOI: 10.1210/clinem/dgag125 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Participants with MASLD showed a blunted ATP response to oral fructose, with only a nonsignificant early drop and recovery by 30 minutes.
Fructose → Human hepatic ATP measured by phosphorus MRS source_derived_draftungraded
Experimental context and source evidence
dose
75 g fructose challenge
duration
60 min
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
37 overweight/obese adults without diabetes, stratified by MASLD
exposure_scope
Isolated fructose, oral
limitations
Small acute component study; the ATP response was blunted in MASLD, not uniformly greater. Metabolite signals are not chronic clinical outcomes.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
37 overweight/obese adults without diabetes, stratified by MASLD
plain_language
Participants with MASLD showed a blunted ATP response to oral fructose, with only a nonsignificant early drop and recovery by 30 minutes.
primary_references
Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption. (2026). https://pubmed.ncbi.nlm.nih.gov/41866318/ DOI: 10.1210/clinem/dgag125
route
Oral solution
tissue
Liver phosphorus-31 MRS
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 269–279
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 37 overweight/obese adults without diabetes, stratified by MASLD · source_derived_draft · unverified_draft
## hfcs-oral-atp-masld Participants with MASLD showed a blunted ATP response to oral fructose, with only a nonsignificant early drop and recovery by 30 minutes. Model/species: 37 overweight/obese adults without diabetes, stratified by MASLD Tissue: Liver phosphorus-31 MRS Exposure: 75 g fructose challenge Route: Oral solution Duration: 60 min Exposure scope: Isolated fructose, oral Limits: Small acute component study; the ATP response was blunted in MASLD, not uniformly greater. Metabolite signals are not chronic clinical outcomes. Reference: Patients with MASLD exhibit in vivo changes in hepatic response to oral fructose consumption. (2026). https://pubmed.ncbi.nlm.nih.gov/41866318/ DOI: 10.1210/clinem/dgag125 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
HFCS beverage dose was associated with increasing postprandial triglycerides; all three sugar doses exceeded the aspartame control.
HFCS-55 → Human postprandial triglyceride response source_derived_draftungraded
Experimental context and source evidence
dose
HFCS-55 beverages at 0%, 10%, 17.5% or 25% energy requirement; 0% aspartame control
duration
Approximately 2 weeks
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
85 adults aged 18-40; nonrandomized double-blinded matched groups
exposure_scope
Direct HFCS-55 evidence
limitations
Short biomarker study; outpatient calories were not fixed and clinical cardiovascular events were not measured. NCT01103921 overlaps HFCS/control participants with the 2021 report.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
85 adults aged 18-40; nonrandomized double-blinded matched groups
plain_language
HFCS beverage dose was associated with increasing postprandial triglycerides; all three sugar doses exceeded the aspartame control.
primary_references
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. (2015). https://pubmed.ncbi.nlm.nih.gov/25904601/ DOI: 10.3945/ajcn.114.100461
route
Oral beverages, with outpatient ad libitum diet and controlled inpatient meals
tissue
Circulating lipids and urate
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 281–291
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 85 adults aged 18-40; nonrandomized double-blinded matched groups · source_derived_draft · unverified_draft
## hfcs-dose-triglycerides HFCS beverage dose was associated with increasing postprandial triglycerides; all three sugar doses exceeded the aspartame control. Model/species: 85 adults aged 18-40; nonrandomized double-blinded matched groups Tissue: Circulating lipids and urate Exposure: HFCS-55 beverages at 0%, 10%, 17.5% or 25% energy requirement; 0% aspartame control Route: Oral beverages, with outpatient ad libitum diet and controlled inpatient meals Duration: Approximately 2 weeks Exposure scope: Direct HFCS-55 evidence Limits: Short biomarker study; outpatient calories were not fixed and clinical cardiovascular events were not measured. NCT01103921 overlaps HFCS/control participants with the 2021 report. Reference: A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. (2015). https://pubmed.ncbi.nlm.nih.gov/25904601/ DOI: 10.3945/ajcn.114.100461 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Fasting LDL cholesterol increased across increasing HFCS beverage doses in the two-week study.
HFCS-55 → Human plasma LDL cholesterol source_derived_draftungraded
Experimental context and source evidence
dose
HFCS-55 beverages at 0%, 10%, 17.5% or 25% energy requirement; 0% aspartame control
duration
Approximately 2 weeks
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
85 adults aged 18-40; nonrandomized double-blinded matched groups
exposure_scope
Direct HFCS-55 evidence
limitations
Short biomarker study; outpatient calories were not fixed and clinical cardiovascular events were not measured. NCT01103921 overlaps HFCS/control participants with the 2021 report.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
85 adults aged 18-40; nonrandomized double-blinded matched groups
plain_language
Fasting LDL cholesterol increased across increasing HFCS beverage doses in the two-week study.
primary_references
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. (2015). https://pubmed.ncbi.nlm.nih.gov/25904601/ DOI: 10.3945/ajcn.114.100461
route
Oral beverages, with outpatient ad libitum diet and controlled inpatient meals
tissue
Circulating lipids and urate
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 293–303
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 85 adults aged 18-40; nonrandomized double-blinded matched groups · source_derived_draft · unverified_draft
## hfcs-dose-ldl Fasting LDL cholesterol increased across increasing HFCS beverage doses in the two-week study. Model/species: 85 adults aged 18-40; nonrandomized double-blinded matched groups Tissue: Circulating lipids and urate Exposure: HFCS-55 beverages at 0%, 10%, 17.5% or 25% energy requirement; 0% aspartame control Route: Oral beverages, with outpatient ad libitum diet and controlled inpatient meals Duration: Approximately 2 weeks Exposure scope: Direct HFCS-55 evidence Limits: Short biomarker study; outpatient calories were not fixed and clinical cardiovascular events were not measured. NCT01103921 overlaps HFCS/control participants with the 2021 report. Reference: A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. (2015). https://pubmed.ncbi.nlm.nih.gov/25904601/ DOI: 10.3945/ajcn.114.100461 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Mean 24-hour urate increased with HFCS dose in the two-week study.
HFCS-55 → Human plasma urate concentration source_derived_draftungraded
Experimental context and source evidence
dose
HFCS-55 beverages at 0%, 10%, 17.5% or 25% energy requirement; 0% aspartame control
duration
Approximately 2 weeks
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
85 adults aged 18-40; nonrandomized double-blinded matched groups
exposure_scope
Direct HFCS-55 evidence
limitations
Short biomarker study; outpatient calories were not fixed and clinical cardiovascular events were not measured. NCT01103921 overlaps HFCS/control participants with the 2021 report.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
85 adults aged 18-40; nonrandomized double-blinded matched groups
plain_language
Mean 24-hour urate increased with HFCS dose in the two-week study.
primary_references
A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. (2015). https://pubmed.ncbi.nlm.nih.gov/25904601/ DOI: 10.3945/ajcn.114.100461
route
Oral beverages, with outpatient ad libitum diet and controlled inpatient meals
tissue
Circulating lipids and urate
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 305–315
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 85 adults aged 18-40; nonrandomized double-blinded matched groups · source_derived_draft · unverified_draft
## hfcs-dose-urate Mean 24-hour urate increased with HFCS dose in the two-week study. Model/species: 85 adults aged 18-40; nonrandomized double-blinded matched groups Tissue: Circulating lipids and urate Exposure: HFCS-55 beverages at 0%, 10%, 17.5% or 25% energy requirement; 0% aspartame control Route: Oral beverages, with outpatient ad libitum diet and controlled inpatient meals Duration: Approximately 2 weeks Exposure scope: Direct HFCS-55 evidence Limits: Short biomarker study; outpatient calories were not fixed and clinical cardiovascular events were not measured. NCT01103921 overlaps HFCS/control participants with the 2021 report. Reference: A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. (2015). https://pubmed.ncbi.nlm.nih.gov/25904601/ DOI: 10.3945/ajcn.114.100461 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
The HFCS group showed a 0.4 +/- 0.2 percentage-point increase in hepatic lipid from baseline; its direct contrast with aspartame was not significant.
HFCS-55 → Human hepatic lipid content measured by imaging source_derived_draftungraded
Experimental context and source evidence
dose
HFCS-55 or sucrose at 25% energy requirement versus aspartame; HFCS n=28, sucrose n=24, control n=23
duration
16 days of beverages, approximately 2 weeks
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
75 adults in nonrandomized double-blinded matched beverage groups
exposure_scope
Direct HFCS-55 comparison
limitations
No random assignment; 66 paired MRI scans, including 23 HFCS. Liver-fat HFCS significance was versus baseline, not established versus aspartame. No detected HFCS-sucrose difference is not universal equivalence. HFCS/control lipid data overlap PMID 25904601.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
75 adults in nonrandomized double-blinded matched beverage groups
plain_language
The HFCS group showed a 0.4 +/- 0.2 percentage-point increase in hepatic lipid from baseline; its direct contrast with aspartame was not significant.
primary_references
Consuming Sucrose- or HFCS-sweetened Beverages Increases Hepatic Lipid and Decreases Insulin Sensitivity in Adults. (2021). https://pubmed.ncbi.nlm.nih.gov/34265055/ DOI: 10.1210/clinem/dgab508
route
Oral 3 servings/day; usual diet outpatient, isocaloric substitutions during inpatient testing
tissue
MRI liver fat, oral-glucose-derived sensitivity, plasma markers
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 317–327
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 75 adults in nonrandomized double-blinded matched beverage groups · source_derived_draft · unverified_draft
## hfcs-liver-fat The HFCS group showed a 0.4 +/- 0.2 percentage-point increase in hepatic lipid from baseline; its direct contrast with aspartame was not significant. Model/species: 75 adults in nonrandomized double-blinded matched beverage groups Tissue: MRI liver fat, oral-glucose-derived sensitivity, plasma markers Exposure: HFCS-55 or sucrose at 25% energy requirement versus aspartame; HFCS n=28, sucrose n=24, control n=23 Route: Oral 3 servings/day; usual diet outpatient, isocaloric substitutions during inpatient testing Duration: 16 days of beverages, approximately 2 weeks Exposure scope: Direct HFCS-55 comparison Limits: No random assignment; 66 paired MRI scans, including 23 HFCS. Liver-fat HFCS significance was versus baseline, not established versus aspartame. No detected HFCS-sucrose difference is not universal equivalence. HFCS/control lipid data overlap PMID 25904601. Reference: Consuming Sucrose- or HFCS-sweetened Beverages Increases Hepatic Lipid and Decreases Insulin Sensitivity in Adults. (2021). https://pubmed.ncbi.nlm.nih.gov/34265055/ DOI: 10.1210/clinem/dgab508 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
HFCS beverages reduced Matsuda insulin sensitivity compared with aspartame in the matched-group intervention.
HFCS-55 → Human Matsuda insulin sensitivity index source_derived_draftungraded
Experimental context and source evidence
dose
HFCS-55 or sucrose at 25% energy requirement versus aspartame; HFCS n=28, sucrose n=24, control n=23
duration
16 days of beverages, approximately 2 weeks
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
75 adults in nonrandomized double-blinded matched beverage groups
exposure_scope
Direct HFCS-55 comparison
limitations
No random assignment; 66 paired MRI scans, including 23 HFCS. Liver-fat HFCS significance was versus baseline, not established versus aspartame. No detected HFCS-sucrose difference is not universal equivalence. HFCS/control lipid data overlap PMID 25904601.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
75 adults in nonrandomized double-blinded matched beverage groups
plain_language
HFCS beverages reduced Matsuda insulin sensitivity compared with aspartame in the matched-group intervention.
primary_references
Consuming Sucrose- or HFCS-sweetened Beverages Increases Hepatic Lipid and Decreases Insulin Sensitivity in Adults. (2021). https://pubmed.ncbi.nlm.nih.gov/34265055/ DOI: 10.1210/clinem/dgab508
route
Oral 3 servings/day; usual diet outpatient, isocaloric substitutions during inpatient testing
tissue
MRI liver fat, oral-glucose-derived sensitivity, plasma markers
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 329–339
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 75 adults in nonrandomized double-blinded matched beverage groups · source_derived_draft · unverified_draft
## hfcs-insulin-sensitivity HFCS beverages reduced Matsuda insulin sensitivity compared with aspartame in the matched-group intervention. Model/species: 75 adults in nonrandomized double-blinded matched beverage groups Tissue: MRI liver fat, oral-glucose-derived sensitivity, plasma markers Exposure: HFCS-55 or sucrose at 25% energy requirement versus aspartame; HFCS n=28, sucrose n=24, control n=23 Route: Oral 3 servings/day; usual diet outpatient, isocaloric substitutions during inpatient testing Duration: 16 days of beverages, approximately 2 weeks Exposure scope: Direct HFCS-55 comparison Limits: No random assignment; 66 paired MRI scans, including 23 HFCS. Liver-fat HFCS significance was versus baseline, not established versus aspartame. No detected HFCS-sucrose difference is not universal equivalence. HFCS/control lipid data overlap PMID 25904601. Reference: Consuming Sucrose- or HFCS-sweetened Beverages Increases Hepatic Lipid and Decreases Insulin Sensitivity in Adults. (2021). https://pubmed.ncbi.nlm.nih.gov/34265055/ DOI: 10.1210/clinem/dgab508 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
No measured metabolic outcome differed significantly between the HFCS and sucrose beverage groups.
HFCS-55 → Human endocrine responses to HFCS versus sucrose source_derived_draftungraded
Experimental context and source evidence
dose
HFCS-55 or sucrose at 25% energy requirement versus aspartame; HFCS n=28, sucrose n=24, control n=23
duration
16 days of beverages, approximately 2 weeks
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
75 adults in nonrandomized double-blinded matched beverage groups
exposure_scope
Direct HFCS-55 comparison
limitations
No random assignment; 66 paired MRI scans, including 23 HFCS. Liver-fat HFCS significance was versus baseline, not established versus aspartame. No detected HFCS-sucrose difference is not universal equivalence. HFCS/control lipid data overlap PMID 25904601.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
75 adults in nonrandomized double-blinded matched beverage groups
plain_language
No measured metabolic outcome differed significantly between the HFCS and sucrose beverage groups.
primary_references
Consuming Sucrose- or HFCS-sweetened Beverages Increases Hepatic Lipid and Decreases Insulin Sensitivity in Adults. (2021). https://pubmed.ncbi.nlm.nih.gov/34265055/ DOI: 10.1210/clinem/dgab508
route
Oral 3 servings/day; usual diet outpatient, isocaloric substitutions during inpatient testing
tissue
MRI liver fat, oral-glucose-derived sensitivity, plasma markers
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 341–351
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 75 adults in nonrandomized double-blinded matched beverage groups · source_derived_draft · unverified_draft
## hfcs-sucrose-comparison No measured metabolic outcome differed significantly between the HFCS and sucrose beverage groups. Model/species: 75 adults in nonrandomized double-blinded matched beverage groups Tissue: MRI liver fat, oral-glucose-derived sensitivity, plasma markers Exposure: HFCS-55 or sucrose at 25% energy requirement versus aspartame; HFCS n=28, sucrose n=24, control n=23 Route: Oral 3 servings/day; usual diet outpatient, isocaloric substitutions during inpatient testing Duration: 16 days of beverages, approximately 2 weeks Exposure scope: Direct HFCS-55 comparison Limits: No random assignment; 66 paired MRI scans, including 23 HFCS. Liver-fat HFCS significance was versus baseline, not established versus aspartame. No detected HFCS-sucrose difference is not universal equivalence. HFCS/control lipid data overlap PMID 25904601. Reference: Consuming Sucrose- or HFCS-sweetened Beverages Increases Hepatic Lipid and Decreases Insulin Sensitivity in Adults. (2021). https://pubmed.ncbi.nlm.nih.gov/34265055/ DOI: 10.1210/clinem/dgab508 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
HFCS and sucrose produced similar 24-hour insulin profiles with isocaloric meals.
HFCS-55 → Human endocrine responses to HFCS versus sucrose source_derived_draftungraded
Experimental context and source evidence
dose
HFCS or sucrose beverages with 3 isocaloric meals; exact sugar allocation not recovered from primary abstract
duration
24-hour profiles
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
34 adults in crossover meal study; 8 men also received pure monosaccharides
exposure_scope
Direct HFCS versus sucrose
limitations
Short feeding study; eight-man fructose/glucose comparison is a subset and does not establish long-term equivalence or appetite control.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
34 adults in crossover meal study; 8 men also received pure monosaccharides
plain_language
HFCS and sucrose produced similar 24-hour insulin profiles with isocaloric meals.
primary_references
Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals. (2008). https://pubmed.ncbi.nlm.nih.gov/18469239/ DOI: 10.1093/ajcn/87.5.1194
route
Oral beverages with meals
tissue
24-hour endocrine and triglyceride profiles
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 353–363
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 34 adults in crossover meal study; 8 men also received pure monosaccharides · source_derived_draft · unverified_draft
## hfcs-acute-insulin HFCS and sucrose produced similar 24-hour insulin profiles with isocaloric meals. Model/species: 34 adults in crossover meal study; 8 men also received pure monosaccharides Tissue: 24-hour endocrine and triglyceride profiles Exposure: HFCS or sucrose beverages with 3 isocaloric meals; exact sugar allocation not recovered from primary abstract Route: Oral beverages with meals Duration: 24-hour profiles Exposure scope: Direct HFCS versus sucrose Limits: Short feeding study; eight-man fructose/glucose comparison is a subset and does not establish long-term equivalence or appetite control. Reference: Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals. (2008). https://pubmed.ncbi.nlm.nih.gov/18469239/ DOI: 10.1093/ajcn/87.5.1194 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
HFCS and sucrose produced similar 24-hour circulating leptin profiles in the crossover study.
HFCS-55 → LEP source_derived_draftungraded
Experimental context and source evidence
dose
HFCS or sucrose beverages with 3 isocaloric meals; exact sugar allocation not recovered from primary abstract
duration
24-hour profiles
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
34 adults in crossover meal study; 8 men also received pure monosaccharides
exposure_scope
Direct HFCS versus sucrose
limitations
Short feeding study; eight-man fructose/glucose comparison is a subset and does not establish long-term equivalence or appetite control.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
34 adults in crossover meal study; 8 men also received pure monosaccharides
plain_language
HFCS and sucrose produced similar 24-hour circulating leptin profiles in the crossover study.
primary_references
Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals. (2008). https://pubmed.ncbi.nlm.nih.gov/18469239/ DOI: 10.1093/ajcn/87.5.1194
route
Oral beverages with meals
tissue
24-hour endocrine and triglyceride profiles
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 365–375
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 34 adults in crossover meal study; 8 men also received pure monosaccharides · source_derived_draft · unverified_draft
## hfcs-acute-leptin HFCS and sucrose produced similar 24-hour circulating leptin profiles in the crossover study. Model/species: 34 adults in crossover meal study; 8 men also received pure monosaccharides Tissue: 24-hour endocrine and triglyceride profiles Exposure: HFCS or sucrose beverages with 3 isocaloric meals; exact sugar allocation not recovered from primary abstract Route: Oral beverages with meals Duration: 24-hour profiles Exposure scope: Direct HFCS versus sucrose Limits: Short feeding study; eight-man fructose/glucose comparison is a subset and does not establish long-term equivalence or appetite control. Reference: Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals. (2008). https://pubmed.ncbi.nlm.nih.gov/18469239/ DOI: 10.1093/ajcn/87.5.1194 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
In the eight-man subset, HFCS and sucrose produced postprandial triglyceride responses comparable to pure fructose.
HFCS-55 → Human postprandial triglyceride response source_derived_draftungraded
Experimental context and source evidence
dose
HFCS or sucrose beverages with 3 isocaloric meals; exact sugar allocation not recovered from primary abstract
duration
24-hour profiles
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
34 adults in crossover meal study; 8 men also received pure monosaccharides
exposure_scope
Direct HFCS versus sucrose
limitations
Short feeding study; eight-man fructose/glucose comparison is a subset and does not establish long-term equivalence or appetite control.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
34 adults in crossover meal study; 8 men also received pure monosaccharides
plain_language
In the eight-man subset, HFCS and sucrose produced postprandial triglyceride responses comparable to pure fructose.
primary_references
Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals. (2008). https://pubmed.ncbi.nlm.nih.gov/18469239/ DOI: 10.1093/ajcn/87.5.1194
route
Oral beverages with meals
tissue
24-hour endocrine and triglyceride profiles
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 377–387
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 34 adults in crossover meal study; 8 men also received pure monosaccharides · source_derived_draft · unverified_draft
## hfcs-acute-tg In the eight-man subset, HFCS and sucrose produced postprandial triglyceride responses comparable to pure fructose. Model/species: 34 adults in crossover meal study; 8 men also received pure monosaccharides Tissue: 24-hour endocrine and triglyceride profiles Exposure: HFCS or sucrose beverages with 3 isocaloric meals; exact sugar allocation not recovered from primary abstract Route: Oral beverages with meals Duration: 24-hour profiles Exposure scope: Direct HFCS versus sucrose Limits: Short feeding study; eight-man fructose/glucose comparison is a subset and does not establish long-term equivalence or appetite control. Reference: Twenty-four-hour endocrine and metabolic profiles following consumption of high-fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals. (2008). https://pubmed.ncbi.nlm.nih.gov/18469239/ DOI: 10.1093/ajcn/87.5.1194 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Fructose beverages increased basal hepatic fractional fatty-acid synthesis/secretion versus control after seven weeks.
Fructose → Human basal hepatic fractional fatty-acid synthesis/secretion source_derived_draftungraded
Experimental context and source evidence
dose
Fructose, sucrose or glucose 80 g/day versus sweetened-beverage abstinence
duration
7 weeks
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
94 healthy men completing randomized beverage intervention
exposure_scope
Component sugars and sucrose
limitations
Total reported energy intake was similar across groups; this was not a metabolic-ward clamp. Fractional fatty-acid synthesis is distinct from total liver fat and VLDL-TG output. No HFCS arm.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
94 healthy men completing randomized beverage intervention
plain_language
Fructose beverages increased basal hepatic fractional fatty-acid synthesis/secretion versus control after seven weeks.
primary_references
Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33684506/ DOI: 10.1016/j.jhep.2021.02.027
route
Oral beverages in addition to usual diet
tissue
Stable-isotope hepatic lipid synthesis
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 389–399
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 94 healthy men completing randomized beverage intervention · source_derived_draft · unverified_draft
## hfcs-component-dnl Fructose beverages increased basal hepatic fractional fatty-acid synthesis/secretion versus control after seven weeks. Model/species: 94 healthy men completing randomized beverage intervention Tissue: Stable-isotope hepatic lipid synthesis Exposure: Fructose, sucrose or glucose 80 g/day versus sweetened-beverage abstinence Route: Oral beverages in addition to usual diet Duration: 7 weeks Exposure scope: Component sugars and sucrose Limits: Total reported energy intake was similar across groups; this was not a metabolic-ward clamp. Fractional fatty-acid synthesis is distinct from total liver fat and VLDL-TG output. No HFCS arm. Reference: Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33684506/ DOI: 10.1016/j.jhep.2021.02.027 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Sucrose beverages also increased basal hepatic fractional fatty-acid synthesis/secretion; glucose did not in the same trial.
Sucrose → Human basal hepatic fractional fatty-acid synthesis/secretion source_derived_draftungraded
Experimental context and source evidence
dose
Fructose, sucrose or glucose 80 g/day versus sweetened-beverage abstinence
duration
7 weeks
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
94 healthy men completing randomized beverage intervention
exposure_scope
Component sugars and sucrose
limitations
Total reported energy intake was similar across groups; this was not a metabolic-ward clamp. Fractional fatty-acid synthesis is distinct from total liver fat and VLDL-TG output. No HFCS arm.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
94 healthy men completing randomized beverage intervention
plain_language
Sucrose beverages also increased basal hepatic fractional fatty-acid synthesis/secretion; glucose did not in the same trial.
primary_references
Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33684506/ DOI: 10.1016/j.jhep.2021.02.027
route
Oral beverages in addition to usual diet
tissue
Stable-isotope hepatic lipid synthesis
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 401–411
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 94 healthy men completing randomized beverage intervention · source_derived_draft · unverified_draft
## hfcs-sucrose-dnl Sucrose beverages also increased basal hepatic fractional fatty-acid synthesis/secretion; glucose did not in the same trial. Model/species: 94 healthy men completing randomized beverage intervention Tissue: Stable-isotope hepatic lipid synthesis Exposure: Fructose, sucrose or glucose 80 g/day versus sweetened-beverage abstinence Route: Oral beverages in addition to usual diet Duration: 7 weeks Exposure scope: Component sugars and sucrose Limits: Total reported energy intake was similar across groups; this was not a metabolic-ward clamp. Fractional fatty-acid synthesis is distinct from total liver fat and VLDL-TG output. No HFCS arm. Reference: Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33684506/ DOI: 10.1016/j.jhep.2021.02.027 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Fructose did not increase basal secretion of newly synthesized VLDL triglyceride in that trial.
Fructose → Human basal secretion of newly synthesized VLDL triglyceride source_derived_draftungraded
Experimental context and source evidence
dose
Fructose, sucrose or glucose 80 g/day versus sweetened-beverage abstinence
duration
7 weeks
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
94 healthy men completing randomized beverage intervention
exposure_scope
Component sugars and sucrose
limitations
Total reported energy intake was similar across groups; this was not a metabolic-ward clamp. Fractional fatty-acid synthesis is distinct from total liver fat and VLDL-TG output. No HFCS arm.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
94 healthy men completing randomized beverage intervention
plain_language
Fructose did not increase basal secretion of newly synthesized VLDL triglyceride in that trial.
primary_references
Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33684506/ DOI: 10.1016/j.jhep.2021.02.027
route
Oral beverages in addition to usual diet
tissue
Stable-isotope hepatic lipid synthesis
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 413–423
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 94 healthy men completing randomized beverage intervention · source_derived_draft · unverified_draft
## hfcs-vldl-null Fructose did not increase basal secretion of newly synthesized VLDL triglyceride in that trial. Model/species: 94 healthy men completing randomized beverage intervention Tissue: Stable-isotope hepatic lipid synthesis Exposure: Fructose, sucrose or glucose 80 g/day versus sweetened-beverage abstinence Route: Oral beverages in addition to usual diet Duration: 7 weeks Exposure scope: Component sugars and sucrose Limits: Total reported energy intake was similar across groups; this was not a metabolic-ward clamp. Fractional fatty-acid synthesis is distinct from total liver fat and VLDL-TG output. No HFCS arm. Reference: Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33684506/ DOI: 10.1016/j.jhep.2021.02.027 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Rats drinking HFCS-55 had the highest hepatic triglyceride and total lipid content among the tested solutions.
HFCS-55 → Rat hepatic triglyceride content source_derived_draftungraded
Experimental context and source evidence
dose
13% w/v HFCS-55, sucrose or fructose solution versus water
duration
8 weeks
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Female rats, seven per group
exposure_scope
Direct HFCS-55 animal evidence
limitations
Hypercaloric animal setting. Expression and fatty-acid composition suggest lipogenesis but are not isotope flux measurements; differences do not establish HFCS superiority/inferiority in humans.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Female rats, seven per group
plain_language
Rats drinking HFCS-55 had the highest hepatic triglyceride and total lipid content among the tested solutions.
primary_references
High-fructose corn syrup-55 consumption alters hepatic lipid metabolism and promotes triglyceride accumulation. (2017). https://pubmed.ncbi.nlm.nih.gov/27768909/ DOI: 10.1016/j.jnutbio.2016.09.010
route
Oral ad libitum solution
tissue
Hepatic lipid and expression endpoints
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 425–435
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Female rats, seven per group · source_derived_draft · unverified_draft
## hfcs-rat-hfcs-lipid Rats drinking HFCS-55 had the highest hepatic triglyceride and total lipid content among the tested solutions. Model/species: Female rats, seven per group Tissue: Hepatic lipid and expression endpoints Exposure: 13% w/v HFCS-55, sucrose or fructose solution versus water Route: Oral ad libitum solution Duration: 8 weeks Exposure scope: Direct HFCS-55 animal evidence Limits: Hypercaloric animal setting. Expression and fatty-acid composition suggest lipogenesis but are not isotope flux measurements; differences do not establish HFCS superiority/inferiority in humans. Reference: High-fructose corn syrup-55 consumption alters hepatic lipid metabolism and promotes triglyceride accumulation. (2017). https://pubmed.ncbi.nlm.nih.gov/27768909/ DOI: 10.1016/j.jnutbio.2016.09.010 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
HFCS-55 exposure was associated with increased hepatic Scd1 expression in female rats.
HFCS-55 → Rat stearoyl-CoA desaturase 1 / Scd1 source_derived_draftungraded
Experimental context and source evidence
dose
13% w/v HFCS-55, sucrose or fructose solution versus water
duration
8 weeks
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Female rats, seven per group
exposure_scope
Direct HFCS-55 animal evidence
limitations
Hypercaloric animal setting. Expression and fatty-acid composition suggest lipogenesis but are not isotope flux measurements; differences do not establish HFCS superiority/inferiority in humans.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Female rats, seven per group
plain_language
HFCS-55 exposure was associated with increased hepatic Scd1 expression in female rats.
primary_references
High-fructose corn syrup-55 consumption alters hepatic lipid metabolism and promotes triglyceride accumulation. (2017). https://pubmed.ncbi.nlm.nih.gov/27768909/ DOI: 10.1016/j.jnutbio.2016.09.010
route
Oral ad libitum solution
tissue
Hepatic lipid and expression endpoints
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 437–447
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Female rats, seven per group · source_derived_draft · unverified_draft
## hfcs-rat-scd1 HFCS-55 exposure was associated with increased hepatic Scd1 expression in female rats. Model/species: Female rats, seven per group Tissue: Hepatic lipid and expression endpoints Exposure: 13% w/v HFCS-55, sucrose or fructose solution versus water Route: Oral ad libitum solution Duration: 8 weeks Exposure scope: Direct HFCS-55 animal evidence Limits: Hypercaloric animal setting. Expression and fatty-acid composition suggest lipogenesis but are not isotope flux measurements; differences do not establish HFCS superiority/inferiority in humans. Reference: High-fructose corn syrup-55 consumption alters hepatic lipid metabolism and promotes triglyceride accumulation. (2017). https://pubmed.ncbi.nlm.nih.gov/27768909/ DOI: 10.1016/j.jnutbio.2016.09.010 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Oral fructose stimulated GLP-1 release in healthy adults, less strongly than isocaloric glucose.
Fructose → Human GLP-1 response to oral fructose source_derived_draftungraded
Experimental context and source evidence
dose
75 g fructose or glucose in 300 mL water after overnight fast
duration
120 min
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Nine healthy adults, paired single-blinded challenges
exposure_scope
Isolated fructose / peptide response
limitations
Pure fructose stimulated some hormones less than glucose, but was not hormonally inert; not an HFCS meal or chronic satiety study.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Nine healthy adults, paired single-blinded challenges
plain_language
Oral fructose stimulated GLP-1 release in healthy adults, less strongly than isocaloric glucose.
primary_references
Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. (2014). https://pubmed.ncbi.nlm.nih.gov/24525020/ DOI: 10.1152/ajpgi.00372.2013
route
Oral solution
tissue
Plasma gut-hormone response
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 449–459
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Nine healthy adults, paired single-blinded challenges · source_derived_draft · unverified_draft
## hfcs-human-glp1 Oral fructose stimulated GLP-1 release in healthy adults, less strongly than isocaloric glucose. Model/species: Nine healthy adults, paired single-blinded challenges Tissue: Plasma gut-hormone response Exposure: 75 g fructose or glucose in 300 mL water after overnight fast Route: Oral solution Duration: 120 min Exposure scope: Isolated fructose / peptide response Limits: Pure fructose stimulated some hormones less than glucose, but was not hormonally inert; not an HFCS meal or chronic satiety study. Reference: Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. (2014). https://pubmed.ncbi.nlm.nih.gov/24525020/ DOI: 10.1152/ajpgi.00372.2013 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Fructose did not stimulate GIP release, whereas glucose did in the paired human challenge.
Fructose → Human GIP response to oral fructose source_derived_draftungraded
Experimental context and source evidence
dose
75 g fructose or glucose in 300 mL water after overnight fast
duration
120 min
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Nine healthy adults, paired single-blinded challenges
exposure_scope
Isolated fructose / peptide response
limitations
Pure fructose stimulated some hormones less than glucose, but was not hormonally inert; not an HFCS meal or chronic satiety study.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Nine healthy adults, paired single-blinded challenges
plain_language
Fructose did not stimulate GIP release, whereas glucose did in the paired human challenge.
primary_references
Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. (2014). https://pubmed.ncbi.nlm.nih.gov/24525020/ DOI: 10.1152/ajpgi.00372.2013
route
Oral solution
tissue
Plasma gut-hormone response
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 461–471
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Nine healthy adults, paired single-blinded challenges · source_derived_draft · unverified_draft
## hfcs-human-gip-null Fructose did not stimulate GIP release, whereas glucose did in the paired human challenge. Model/species: Nine healthy adults, paired single-blinded challenges Tissue: Plasma gut-hormone response Exposure: 75 g fructose or glucose in 300 mL water after overnight fast Route: Oral solution Duration: 120 min Exposure scope: Isolated fructose / peptide response Limits: Pure fructose stimulated some hormones less than glucose, but was not hormonally inert; not an HFCS meal or chronic satiety study. Reference: Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. (2014). https://pubmed.ncbi.nlm.nih.gov/24525020/ DOI: 10.1152/ajpgi.00372.2013 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Fructose stimulated GLP-1 secretion in mouse GLUTag cells with a reported EC50 of 0.155 mM.
Fructose → GLP-1 secretion from mouse GLUTag cells source_derived_draftungraded
Experimental context and source evidence
dose
Fructose concentration series, EC50 0.155 mM; blocker experiment 10 mM fructose plus 340 micromolar diazoxide
duration
2 h
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Mouse GLUTag enteroendocrine cell line
exposure_scope
Isolated fructose / drug-peptide assay
limitations
Pharmacological channel control in a cell line does not establish a human drug-food interaction or a reason to consume fructose therapeutically.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Mouse GLUTag enteroendocrine cell line
plain_language
Fructose stimulated GLP-1 secretion in mouse GLUTag cells with a reported EC50 of 0.155 mM.
primary_references
Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. (2014). https://pubmed.ncbi.nlm.nih.gov/24525020/ DOI: 10.1152/ajpgi.00372.2013
route
In vitro sugar and drug exposure
tissue
GLP-1 secretion assay
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 473–483
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Mouse GLUTag enteroendocrine cell line · source_derived_draft · unverified_draft
## hfcs-cell-glp1 Fructose stimulated GLP-1 secretion in mouse GLUTag cells with a reported EC50 of 0.155 mM. Model/species: Mouse GLUTag enteroendocrine cell line Tissue: GLP-1 secretion assay Exposure: Fructose concentration series, EC50 0.155 mM; blocker experiment 10 mM fructose plus 340 micromolar diazoxide Route: In vitro sugar and drug exposure Duration: 2 h Exposure scope: Isolated fructose / drug-peptide assay Limits: Pharmacological channel control in a cell line does not establish a human drug-food interaction or a reason to consume fructose therapeutically. Reference: Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. (2014). https://pubmed.ncbi.nlm.nih.gov/24525020/ DOI: 10.1152/ajpgi.00372.2013 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Diazoxide at 340 micromolar abolished fructose-stimulated GLP-1 secretion in GLUTag cells.
Diazoxide → GLP-1 secretion from mouse GLUTag cells source_derived_draftungraded
Experimental context and source evidence
availability_state
machinery_impairment Imported condition classification; unverified.
dose
Fructose concentration series, EC50 0.155 mM; blocker experiment 10 mM fructose plus 340 micromolar diazoxide
duration
2 h
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Mouse GLUTag enteroendocrine cell line
exposure_scope
Isolated fructose / drug-peptide assay
limitations
Pharmacological channel control in a cell line does not establish a human drug-food interaction or a reason to consume fructose therapeutically.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Mouse GLUTag enteroendocrine cell line
plain_language
Diazoxide at 340 micromolar abolished fructose-stimulated GLP-1 secretion in GLUTag cells.
primary_references
Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. (2014). https://pubmed.ncbi.nlm.nih.gov/24525020/ DOI: 10.1152/ajpgi.00372.2013
route
In vitro sugar and drug exposure
tissue
GLP-1 secretion assay
trigger_kind
machinery_impairment Imported condition classification; unverified.
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 485–495
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Mouse GLUTag enteroendocrine cell line · source_derived_draft · unverified_draft
## hfcs-diazoxide Diazoxide at 340 micromolar abolished fructose-stimulated GLP-1 secretion in GLUTag cells. Model/species: Mouse GLUTag enteroendocrine cell line Tissue: GLP-1 secretion assay Exposure: Fructose concentration series, EC50 0.155 mM; blocker experiment 10 mM fructose plus 340 micromolar diazoxide Route: In vitro sugar and drug exposure Duration: 2 h Exposure scope: Isolated fructose / drug-peptide assay Limits: Pharmacological channel control in a cell line does not establish a human drug-food interaction or a reason to consume fructose therapeutically. Reference: Fructose stimulates GLP-1 but not GIP secretion in mice, rats, and humans. (2014). https://pubmed.ncbi.nlm.nih.gov/24525020/ DOI: 10.1152/ajpgi.00372.2013 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
High-fructose feeding worsened copper status in the rat dietary experiment.
Fructose → Copper status in fructose-fed rats source_derived_draftungraded
Experimental context and source evidence
dose
Dietary copper 6 or 1.6 mg/kg diet; water with or without 30% w/v fructose
duration
4 weeks
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Male weanling Sprague-Dawley rats
exposure_scope
Isolated fructose with copper restriction
limitations
High-fructose component experiment. Copper concentrations refer to diet, not body weight. Ctr1 expression is not direct copper flux, and human HFCS-induced copper deficiency is not established.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Male weanling Sprague-Dawley rats
plain_language
High-fructose feeding worsened copper status in the rat dietary experiment.
primary_references
High fructose feeding induces copper deficiency in Sprague-Dawley rats: a novel mechanism for obesity related fatty liver. (2012). https://pubmed.ncbi.nlm.nih.gov/21781943/ DOI: 10.1016/j.jhep.2011.05.030
route
Oral diet and drinking water
tissue
Copper status, duodenum and hepatic triglyceride
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 497–507
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Male weanling Sprague-Dawley rats · source_derived_draft · unverified_draft
## hfcs-copper-status High-fructose feeding worsened copper status in the rat dietary experiment. Model/species: Male weanling Sprague-Dawley rats Tissue: Copper status, duodenum and hepatic triglyceride Exposure: Dietary copper 6 or 1.6 mg/kg diet; water with or without 30% w/v fructose Route: Oral diet and drinking water Duration: 4 weeks Exposure scope: Isolated fructose with copper restriction Limits: High-fructose component experiment. Copper concentrations refer to diet, not body weight. Ctr1 expression is not direct copper flux, and human HFCS-induced copper deficiency is not established. Reference: High fructose feeding induces copper deficiency in Sprague-Dawley rats: a novel mechanism for obesity related fatty liver. (2012). https://pubmed.ncbi.nlm.nih.gov/21781943/ DOI: 10.1016/j.jhep.2011.05.030 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Fructose feeding prevented the duodenal Ctr1 increase otherwise observed with marginal copper deficiency in rats.
Fructose → Rat copper transporter 1 / Slc31a1 source_derived_draftungraded
Experimental context and source evidence
availability_state
nutrient_deficiency Imported condition classification; unverified.
dose
Dietary copper 6 or 1.6 mg/kg diet; water with or without 30% w/v fructose
duration
4 weeks
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Male weanling Sprague-Dawley rats
exposure_scope
Isolated fructose with copper restriction
limitations
High-fructose component experiment. Copper concentrations refer to diet, not body weight. Ctr1 expression is not direct copper flux, and human HFCS-induced copper deficiency is not established.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Male weanling Sprague-Dawley rats
plain_language
Fructose feeding prevented the duodenal Ctr1 increase otherwise observed with marginal copper deficiency in rats.
primary_references
High fructose feeding induces copper deficiency in Sprague-Dawley rats: a novel mechanism for obesity related fatty liver. (2012). https://pubmed.ncbi.nlm.nih.gov/21781943/ DOI: 10.1016/j.jhep.2011.05.030
route
Oral diet and drinking water
tissue
Copper status, duodenum and hepatic triglyceride
trigger_kind
nutrient_deficiency Imported condition classification; unverified.
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 509–519
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Male weanling Sprague-Dawley rats · source_derived_draft · unverified_draft
## hfcs-copper-transporter Fructose feeding prevented the duodenal Ctr1 increase otherwise observed with marginal copper deficiency in rats. Model/species: Male weanling Sprague-Dawley rats Tissue: Copper status, duodenum and hepatic triglyceride Exposure: Dietary copper 6 or 1.6 mg/kg diet; water with or without 30% w/v fructose Route: Oral diet and drinking water Duration: 4 weeks Exposure scope: Isolated fructose with copper restriction Limits: High-fructose component experiment. Copper concentrations refer to diet, not body weight. Ctr1 expression is not direct copper flux, and human HFCS-induced copper deficiency is not established. Reference: High fructose feeding induces copper deficiency in Sprague-Dawley rats: a novel mechanism for obesity related fatty liver. (2012). https://pubmed.ncbi.nlm.nih.gov/21781943/ DOI: 10.1016/j.jhep.2011.05.030 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
The combination of marginal copper deficiency and fructose feeding increased hepatic triglyceride and liver injury in rats.
Fructose → Rat hepatic triglyceride content source_derived_draftungraded
Experimental context and source evidence
availability_state
nutrient_deficiency Imported condition classification; unverified.
dose
Dietary copper 6 or 1.6 mg/kg diet; water with or without 30% w/v fructose
duration
4 weeks
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Male weanling Sprague-Dawley rats
exposure_scope
Isolated fructose with copper restriction
limitations
High-fructose component experiment. Copper concentrations refer to diet, not body weight. Ctr1 expression is not direct copper flux, and human HFCS-induced copper deficiency is not established.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Male weanling Sprague-Dawley rats
plain_language
The combination of marginal copper deficiency and fructose feeding increased hepatic triglyceride and liver injury in rats.
primary_references
High fructose feeding induces copper deficiency in Sprague-Dawley rats: a novel mechanism for obesity related fatty liver. (2012). https://pubmed.ncbi.nlm.nih.gov/21781943/ DOI: 10.1016/j.jhep.2011.05.030
route
Oral diet and drinking water
tissue
Copper status, duodenum and hepatic triglyceride
trigger_kind
nutrient_deficiency Imported condition classification; unverified.
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 521–531
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Male weanling Sprague-Dawley rats · source_derived_draft · unverified_draft
## hfcs-copper-liver The combination of marginal copper deficiency and fructose feeding increased hepatic triglyceride and liver injury in rats. Model/species: Male weanling Sprague-Dawley rats Tissue: Copper status, duodenum and hepatic triglyceride Exposure: Dietary copper 6 or 1.6 mg/kg diet; water with or without 30% w/v fructose Route: Oral diet and drinking water Duration: 4 weeks Exposure scope: Isolated fructose with copper restriction Limits: High-fructose component experiment. Copper concentrations refer to diet, not body weight. Ctr1 expression is not direct copper flux, and human HFCS-induced copper deficiency is not established. Reference: High fructose feeding induces copper deficiency in Sprague-Dawley rats: a novel mechanism for obesity related fatty liver. (2012). https://pubmed.ncbi.nlm.nih.gov/21781943/ DOI: 10.1016/j.jhep.2011.05.030 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Allopurinol lowered serum urate during the high-dose fructose intervention.
Allopurinol → Human plasma urate concentration source_derived_draftungraded
Experimental context and source evidence
dose
200 g fructose/day with or without allopurinol; drug dose not recovered in accessed abstract
duration
2 weeks
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
74 adult men in randomized fructose-loading intervention
exposure_scope
Isolated fructose / drug perturbation
limitations
Very high pure-fructose dose; allopurinol did not correct every outcome. Pharmacological rescue does not prove sole mediation by urate or justify treatment of ordinary HFCS intake.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
74 adult men in randomized fructose-loading intervention
plain_language
Allopurinol lowered serum urate during the high-dose fructose intervention.
primary_references
Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. (2010). https://pubmed.ncbi.nlm.nih.gov/20029377/ DOI: 10.1038/ijo.2009.259
route
Oral fructose and oral drug
tissue
Urate, ambulatory blood pressure and metabolic markers
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 533–543
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 74 adult men in randomized fructose-loading intervention · source_derived_draft · unverified_draft
## hfcs-allopurinol-urate Allopurinol lowered serum urate during the high-dose fructose intervention. Model/species: 74 adult men in randomized fructose-loading intervention Tissue: Urate, ambulatory blood pressure and metabolic markers Exposure: 200 g fructose/day with or without allopurinol; drug dose not recovered in accessed abstract Route: Oral fructose and oral drug Duration: 2 weeks Exposure scope: Isolated fructose / drug perturbation Limits: Very high pure-fructose dose; allopurinol did not correct every outcome. Pharmacological rescue does not prove sole mediation by urate or justify treatment of ordinary HFCS intake. Reference: Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. (2010). https://pubmed.ncbi.nlm.nih.gov/20029377/ DOI: 10.1038/ijo.2009.259 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Allopurinol prevented the fructose-associated increase in 24-hour diastolic and daytime systolic/diastolic blood pressure.
Allopurinol → Human ambulatory blood pressure during experimental fructose loading source_derived_draftungraded
Experimental context and source evidence
dose
200 g fructose/day with or without allopurinol; drug dose not recovered in accessed abstract
duration
2 weeks
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
74 adult men in randomized fructose-loading intervention
exposure_scope
Isolated fructose / drug perturbation
limitations
Very high pure-fructose dose; allopurinol did not correct every outcome. Pharmacological rescue does not prove sole mediation by urate or justify treatment of ordinary HFCS intake.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
74 adult men in randomized fructose-loading intervention
plain_language
Allopurinol prevented the fructose-associated increase in 24-hour diastolic and daytime systolic/diastolic blood pressure.
primary_references
Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. (2010). https://pubmed.ncbi.nlm.nih.gov/20029377/ DOI: 10.1038/ijo.2009.259
route
Oral fructose and oral drug
tissue
Urate, ambulatory blood pressure and metabolic markers
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 545–555
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 74 adult men in randomized fructose-loading intervention · source_derived_draft · unverified_draft
## hfcs-allopurinol-bp Allopurinol prevented the fructose-associated increase in 24-hour diastolic and daytime systolic/diastolic blood pressure. Model/species: 74 adult men in randomized fructose-loading intervention Tissue: Urate, ambulatory blood pressure and metabolic markers Exposure: 200 g fructose/day with or without allopurinol; drug dose not recovered in accessed abstract Route: Oral fructose and oral drug Duration: 2 weeks Exposure scope: Isolated fructose / drug perturbation Limits: Very high pure-fructose dose; allopurinol did not correct every outcome. Pharmacological rescue does not prove sole mediation by urate or justify treatment of ordinary HFCS intake. Reference: Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. (2010). https://pubmed.ncbi.nlm.nih.gov/20029377/ DOI: 10.1038/ijo.2009.259 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Allopurinol did not reduce the HOMA insulin-resistance index during the fructose-loading trial.
Allopurinol → Human HOMA insulin-resistance index during fructose loading source_derived_draftungraded
Experimental context and source evidence
dose
200 g fructose/day with or without allopurinol; drug dose not recovered in accessed abstract
duration
2 weeks
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
74 adult men in randomized fructose-loading intervention
exposure_scope
Isolated fructose / drug perturbation
limitations
Very high pure-fructose dose; allopurinol did not correct every outcome. Pharmacological rescue does not prove sole mediation by urate or justify treatment of ordinary HFCS intake.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
74 adult men in randomized fructose-loading intervention
plain_language
Allopurinol did not reduce the HOMA insulin-resistance index during the fructose-loading trial.
primary_references
Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. (2010). https://pubmed.ncbi.nlm.nih.gov/20029377/ DOI: 10.1038/ijo.2009.259
route
Oral fructose and oral drug
tissue
Urate, ambulatory blood pressure and metabolic markers
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 557–567
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 74 adult men in randomized fructose-loading intervention · source_derived_draft · unverified_draft
## hfcs-allopurinol-homa-null Allopurinol did not reduce the HOMA insulin-resistance index during the fructose-loading trial. Model/species: 74 adult men in randomized fructose-loading intervention Tissue: Urate, ambulatory blood pressure and metabolic markers Exposure: 200 g fructose/day with or without allopurinol; drug dose not recovered in accessed abstract Route: Oral fructose and oral drug Duration: 2 weeks Exposure scope: Isolated fructose / drug perturbation Limits: Very high pure-fructose dose; allopurinol did not correct every outcome. Pharmacological rescue does not prove sole mediation by urate or justify treatment of ordinary HFCS intake. Reference: Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. (2010). https://pubmed.ncbi.nlm.nih.gov/20029377/ DOI: 10.1038/ijo.2009.259 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
PF-06835919 inhibited labeled fructose-1-phosphate formation in primary human hepatocytes.
PF-06835919 → Fructose-1-phosphate formation in primary human hepatocytes source_derived_draftungraded
Experimental context and source evidence
dose
PF-06835919 concentration series; 10 mM labeled fructose
duration
30 min pretreatment; 20 min fructose reaction
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Primary human hepatocytes
exposure_scope
Isolated fructose / investigational drug
limitations
Functional KHK inhibition in cells; PF-06835919 is investigational. Study sponsored/conducted by industry; pharmacological target engagement is not dietary efficacy.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Primary human hepatocytes
plain_language
PF-06835919 inhibited labeled fructose-1-phosphate formation in primary human hepatocytes.
primary_references
Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. (2021). https://pubmed.ncbi.nlm.nih.gov/33667726/ DOI: 10.1016/j.molmet.2021.101196
route
In vitro inhibitor pretreatment and fructose addition
tissue
Labeled fructose-1-phosphate production
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 569–579
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Primary human hepatocytes · source_derived_draft · unverified_draft
## hfcs-pf-hepatocytes PF-06835919 inhibited labeled fructose-1-phosphate formation in primary human hepatocytes. Model/species: Primary human hepatocytes Tissue: Labeled fructose-1-phosphate production Exposure: PF-06835919 concentration series; 10 mM labeled fructose Route: In vitro inhibitor pretreatment and fructose addition Duration: 30 min pretreatment; 20 min fructose reaction Exposure scope: Isolated fructose / investigational drug Limits: Functional KHK inhibition in cells; PF-06835919 is investigational. Study sponsored/conducted by industry; pharmacological target engagement is not dietary efficacy. Reference: Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. (2021). https://pubmed.ncbi.nlm.nih.gov/33667726/ DOI: 10.1016/j.molmet.2021.101196 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
PF-06835919 reduced fructose-associated nuclear ChREBP localization in primary rat hepatocytes.
PF-06835919 → Rat carbohydrate-responsive element-binding protein / ChREBP source_derived_draftungraded
Experimental context and source evidence
dose
10 mM fructose with or without 30 micromolar PF-06835919
duration
Overnight
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Primary rat hepatocytes
exposure_scope
Isolated fructose / investigational drug
limitations
Cell-model transcriptional effect; not established human lipid or disease prevention.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Primary rat hepatocytes
plain_language
PF-06835919 reduced fructose-associated nuclear ChREBP localization in primary rat hepatocytes.
primary_references
Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. (2021). https://pubmed.ncbi.nlm.nih.gov/33667726/ DOI: 10.1016/j.molmet.2021.101196
route
In vitro exposure
tissue
ChREBP nuclear localization
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 581–591
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Primary rat hepatocytes · source_derived_draft · unverified_draft
## hfcs-pf-chrebp PF-06835919 reduced fructose-associated nuclear ChREBP localization in primary rat hepatocytes. Model/species: Primary rat hepatocytes Tissue: ChREBP nuclear localization Exposure: 10 mM fructose with or without 30 micromolar PF-06835919 Route: In vitro exposure Duration: Overnight Exposure scope: Isolated fructose / investigational drug Limits: Cell-model transcriptional effect; not established human lipid or disease prevention. Reference: Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. (2021). https://pubmed.ncbi.nlm.nih.gov/33667726/ DOI: 10.1016/j.molmet.2021.101196 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
PF-06835919 at 300 mg/day reduced liver fat relative to placebo by a reported 18.73% after six weeks.
PF-06835919 → Human hepatic lipid content measured by imaging source_derived_draftungraded
Experimental context and source evidence
dose
PF-06835919 75 or 300 mg once daily versus placebo
duration
6 weeks
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
53 randomized adults with NAFLD; 48 completed phase 2a trial
exposure_scope
Fructose-pathway intervention, not an HFCS challenge
limitations
Small Pfizer-sponsored trial; 300 mg change was relative liver fat, not 18.73 percentage points. Not evidence of an approved drug or proof that HFCS caused each participant's disease.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
53 randomized adults with NAFLD; 48 completed phase 2a trial
plain_language
PF-06835919 at 300 mg/day reduced liver fat relative to placebo by a reported 18.73% after six weeks.
primary_references
Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial. (2021). https://pubmed.ncbi.nlm.nih.gov/35590219/ DOI: 10.1016/j.medj.2021.04.007
route
Oral drug; no controlled HFCS exposure
tissue
MRI proton-density liver fat
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 593–603
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 53 randomized adults with NAFLD; 48 completed phase 2a trial · source_derived_draft · unverified_draft
## hfcs-pf-human-liver PF-06835919 at 300 mg/day reduced liver fat relative to placebo by a reported 18.73% after six weeks. Model/species: 53 randomized adults with NAFLD; 48 completed phase 2a trial Tissue: MRI proton-density liver fat Exposure: PF-06835919 75 or 300 mg once daily versus placebo Route: Oral drug; no controlled HFCS exposure Duration: 6 weeks Exposure scope: Fructose-pathway intervention, not an HFCS challenge Limits: Small Pfizer-sponsored trial; 300 mg change was relative liver fat, not 18.73 percentage points. Not evidence of an approved drug or proof that HFCS caused each participant's disease. Reference: Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial. (2021). https://pubmed.ncbi.nlm.nih.gov/35590219/ DOI: 10.1016/j.medj.2021.04.007 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
The 75 mg/day PF-06835919 arm did not show a significant liver-fat reduction versus placebo.
PF-06835919 → Human hepatic lipid content measured by imaging source_derived_draftungraded
Experimental context and source evidence
dose
PF-06835919 75 or 300 mg once daily versus placebo
duration
6 weeks
evidence_access
Primary abstract/metadata; unrecovered methods explicitly retained.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
53 randomized adults with NAFLD; 48 completed phase 2a trial
exposure_scope
Fructose-pathway intervention, not an HFCS challenge
limitations
Small Pfizer-sponsored trial; 300 mg change was relative liver fat, not 18.73 percentage points. Not evidence of an approved drug or proof that HFCS caused each participant's disease.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
53 randomized adults with NAFLD; 48 completed phase 2a trial
plain_language
The 75 mg/day PF-06835919 arm did not show a significant liver-fat reduction versus placebo.
primary_references
Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial. (2021). https://pubmed.ncbi.nlm.nih.gov/35590219/ DOI: 10.1016/j.medj.2021.04.007
route
Oral drug; no controlled HFCS exposure
tissue
MRI proton-density liver fat
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 605–615
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · 53 randomized adults with NAFLD; 48 completed phase 2a trial · source_derived_draft · unverified_draft
## hfcs-pf-low-dose-null The 75 mg/day PF-06835919 arm did not show a significant liver-fat reduction versus placebo. Model/species: 53 randomized adults with NAFLD; 48 completed phase 2a trial Tissue: MRI proton-density liver fat Exposure: PF-06835919 75 or 300 mg once daily versus placebo Route: Oral drug; no controlled HFCS exposure Duration: 6 weeks Exposure scope: Fructose-pathway intervention, not an HFCS challenge Limits: Small Pfizer-sponsored trial; 300 mg change was relative liver fat, not 18.73 percentage points. Not evidence of an approved drug or proof that HFCS caused each participant's disease. Reference: Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: A randomized phase 2 trial. (2021). https://pubmed.ncbi.nlm.nih.gov/35590219/ DOI: 10.1016/j.medj.2021.04.007 Access: Primary abstract/metadata; unrecovered methods explicitly retained.
Complete structured claim and evidence
Restricted daily HFCS gavage increased large and high-grade intestinal tumors in Apc-deficient mice without inducing obesity.
HFCS-55 → Growth of established intestinal tumors in Apc-deficient mice source_derived_draftungraded
Experimental context and source evidence
dose
400 microliters of 25% HFCS solution daily, approximately 3% of mouse daily calories
duration
8 weeks; acute bolus for ATP analysis
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Genetically Apc-deficient mice predisposed to intestinal adenomas
exposure_scope
Direct HFCS in predisposed mice
limitations
Growth of predisposed mouse tumors, not initiation of cancer in healthy humans. Total tumor number was similar in the main comparison; human-equivalent risk is unresolved.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Genetically Apc-deficient mice predisposed to intestinal adenomas
plain_language
Restricted daily HFCS gavage increased large and high-grade intestinal tumors in Apc-deficient mice without inducing obesity.
primary_references
High-fructose corn syrup enhances intestinal tumor growth in mice. (2019). https://pubmed.ncbi.nlm.nih.gov/30898933/ DOI: 10.1126/science.aat8515
route
Oral gavage; Khk or Fasn deletion where specified
tissue
Tumor size/grade and metabolic perturbations
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 617–627
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Genetically Apc-deficient mice predisposed to intestinal adenomas · source_derived_draft · unverified_draft
## hfcs-tumor-growth Restricted daily HFCS gavage increased large and high-grade intestinal tumors in Apc-deficient mice without inducing obesity. Model/species: Genetically Apc-deficient mice predisposed to intestinal adenomas Tissue: Tumor size/grade and metabolic perturbations Exposure: 400 microliters of 25% HFCS solution daily, approximately 3% of mouse daily calories Route: Oral gavage; Khk or Fasn deletion where specified Duration: 8 weeks; acute bolus for ATP analysis Exposure scope: Direct HFCS in predisposed mice Limits: Growth of predisposed mouse tumors, not initiation of cancer in healthy humans. Total tumor number was similar in the main comparison; human-equivalent risk is unresolved. Reference: High-fructose corn syrup enhances intestinal tumor growth in mice. (2019). https://pubmed.ncbi.nlm.nih.gov/30898933/ DOI: 10.1126/science.aat8515 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Khk deletion abolished HFCS enhancement of tumor growth and grade in Apc-deficient mice.
Mouse ketohexokinase / Khk → Growth of established intestinal tumors in Apc-deficient mice source_derived_draftungraded
Experimental context and source evidence
availability_state
machinery_impairment Imported condition classification; unverified.
dose
400 microliters of 25% HFCS solution daily, approximately 3% of mouse daily calories
duration
8 weeks; acute bolus for ATP analysis
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Genetically Apc-deficient mice predisposed to intestinal adenomas
exposure_scope
Direct HFCS in predisposed mice
limitations
Growth of predisposed mouse tumors, not initiation of cancer in healthy humans. Total tumor number was similar in the main comparison; human-equivalent risk is unresolved.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Genetically Apc-deficient mice predisposed to intestinal adenomas
plain_language
Khk deletion abolished HFCS enhancement of tumor growth and grade in Apc-deficient mice.
primary_references
High-fructose corn syrup enhances intestinal tumor growth in mice. (2019). https://pubmed.ncbi.nlm.nih.gov/30898933/ DOI: 10.1126/science.aat8515
route
Oral gavage; Khk or Fasn deletion where specified
tissue
Tumor size/grade and metabolic perturbations
trigger_kind
machinery_impairment Imported condition classification; unverified.
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 629–639
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Genetically Apc-deficient mice predisposed to intestinal adenomas · source_derived_draft · unverified_draft
## hfcs-tumor-khk-deletion Khk deletion abolished HFCS enhancement of tumor growth and grade in Apc-deficient mice. Model/species: Genetically Apc-deficient mice predisposed to intestinal adenomas Tissue: Tumor size/grade and metabolic perturbations Exposure: 400 microliters of 25% HFCS solution daily, approximately 3% of mouse daily calories Route: Oral gavage; Khk or Fasn deletion where specified Duration: 8 weeks; acute bolus for ATP analysis Exposure scope: Direct HFCS in predisposed mice Limits: Growth of predisposed mouse tumors, not initiation of cancer in healthy humans. Total tumor number was similar in the main comparison; human-equivalent risk is unresolved. Reference: High-fructose corn syrup enhances intestinal tumor growth in mice. (2019). https://pubmed.ncbi.nlm.nih.gov/30898933/ DOI: 10.1126/science.aat8515 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Tumor Fasn deletion abolished the growth-enhancing effect of HFCS in Apc-deficient mice.
Mouse fatty acid synthase / Fasn → Growth of established intestinal tumors in Apc-deficient mice source_derived_draftungraded
Experimental context and source evidence
availability_state
machinery_impairment Imported condition classification; unverified.
dose
400 microliters of 25% HFCS solution daily, approximately 3% of mouse daily calories
duration
8 weeks; acute bolus for ATP analysis
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Genetically Apc-deficient mice predisposed to intestinal adenomas
exposure_scope
Direct HFCS in predisposed mice
limitations
Growth of predisposed mouse tumors, not initiation of cancer in healthy humans. Total tumor number was similar in the main comparison; human-equivalent risk is unresolved.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Genetically Apc-deficient mice predisposed to intestinal adenomas
plain_language
Tumor Fasn deletion abolished the growth-enhancing effect of HFCS in Apc-deficient mice.
primary_references
High-fructose corn syrup enhances intestinal tumor growth in mice. (2019). https://pubmed.ncbi.nlm.nih.gov/30898933/ DOI: 10.1126/science.aat8515
route
Oral gavage; Khk or Fasn deletion where specified
tissue
Tumor size/grade and metabolic perturbations
trigger_kind
machinery_impairment Imported condition classification; unverified.
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 641–651
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Genetically Apc-deficient mice predisposed to intestinal adenomas · source_derived_draft · unverified_draft
## hfcs-tumor-fasn-deletion Tumor Fasn deletion abolished the growth-enhancing effect of HFCS in Apc-deficient mice. Model/species: Genetically Apc-deficient mice predisposed to intestinal adenomas Tissue: Tumor size/grade and metabolic perturbations Exposure: 400 microliters of 25% HFCS solution daily, approximately 3% of mouse daily calories Route: Oral gavage; Khk or Fasn deletion where specified Duration: 8 weeks; acute bolus for ATP analysis Exposure scope: Direct HFCS in predisposed mice Limits: Growth of predisposed mouse tumors, not initiation of cancer in healthy humans. Total tumor number was similar in the main comparison; human-equivalent risk is unresolved. Reference: High-fructose corn syrup enhances intestinal tumor growth in mice. (2019). https://pubmed.ncbi.nlm.nih.gov/30898933/ DOI: 10.1126/science.aat8515 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
An acute HFCS bolus lowered ATP in Apc-deficient intestinal tumors; the change was absent with Khk deletion.
HFCS-55 → ATP content in Apc-deficient mouse intestinal tumors source_derived_draftungraded
Experimental context and source evidence
dose
400 microliters of 25% HFCS solution daily, approximately 3% of mouse daily calories
duration
8 weeks; acute bolus for ATP analysis
evidence_access
Primary full-text methods/results and metadata inspected.
evidence_scope
literature_reviewed; source-specific curation
experimental_model
Genetically Apc-deficient mice predisposed to intestinal adenomas
exposure_scope
Direct HFCS in predisposed mice
limitations
Growth of predisposed mouse tumors, not initiation of cancer in healthy humans. Total tumor number was similar in the main comparison; human-equivalent risk is unresolved.
nutrient_topic
HFCS chapter: actual formulation studies, component biochemistry and interventions are explicitly distinguished. · High-Fructose Corn Syrup / HFCS
organism
Genetically Apc-deficient mice predisposed to intestinal adenomas
plain_language
An acute HFCS bolus lowered ATP in Apc-deficient intestinal tumors; the change was absent with Khk deletion.
primary_references
High-fructose corn syrup enhances intestinal tumor growth in mice. (2019). https://pubmed.ncbi.nlm.nih.gov/30898933/ DOI: 10.1126/science.aat8515
route
Oral gavage; Khk or Fasn deletion where specified
tissue
Tumor size/grade and metabolic perturbations
High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20) · lines 653–663
Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · supports · Genetically Apc-deficient mice predisposed to intestinal adenomas · source_derived_draft · unverified_draft
## hfcs-tumor-atp An acute HFCS bolus lowered ATP in Apc-deficient intestinal tumors; the change was absent with Khk deletion. Model/species: Genetically Apc-deficient mice predisposed to intestinal adenomas Tissue: Tumor size/grade and metabolic perturbations Exposure: 400 microliters of 25% HFCS solution daily, approximately 3% of mouse daily calories Route: Oral gavage; Khk or Fasn deletion where specified Duration: 8 weeks; acute bolus for ATP analysis Exposure scope: Direct HFCS in predisposed mice Limits: Growth of predisposed mouse tumors, not initiation of cancer in healthy humans. Total tumor number was similar in the main comparison; human-equivalent risk is unresolved. Reference: High-fructose corn syrup enhances intestinal tumor growth in mice. (2019). https://pubmed.ncbi.nlm.nih.gov/30898933/ DOI: 10.1126/science.aat8515 Access: Primary full-text methods/results and metadata inspected.
Complete structured claim and evidence
Normal intestinal SGLT1 couples glucose entry to the inward sodium electrochemical gradient.
Human sodium/glucose cotransporter SGLT1 / SLC5A1 → D-glucose source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/sodium-research/2008213.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "ba4e32dc5111895acfe9e109cf57a7e07bc3c4e07e82ad3b4f7715cfaf10af74", "start_char": 0, "end_char": 1357, "text_sha256": "ba4e32dc5111895acfe9e109cf57a7e07bc3c4e07e82ad3b4f7715cfaf10af74"}
experimental_model
Family segregation and Xenopus oocyte transport assay
exposure
Disease-associated SGLT1 missense variant versus normal transporter
limitations
A genetic transporter defect is not sodium dietary deficiency; the sugar-malabsorption phenotype must not be presented as a reason to add salt.
nutrient_topic
Sodium research collection; topical membership is not evidence of a direct dietary effect. · Sodium
organism
Human SGLT1 expressed in frog oocytes
plain_language
A sodium gradient helps intestinal cells take up glucose.
primary_references
[sodium-p2008213] Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. (1991). https://pubmed.ncbi.nlm.nih.gov/2008213/ DOI: 10.1038/350354a0
tissue_or_cell_type
Intestinal brush border
transport_effect
raises Couples glucose entry to the inward sodium electrochemical gradient.
transport_pool
the enterocyte interior Couples glucose entry to the inward sodium electrochemical gradient.
Sodium: gradients, nutrient transport, fluid regulation and loss states (2026-09-17) · lines 291–302
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Family segregation and Xenopus oocyte transport assay · source_derived_draft · unverified_draft
### sodium-sglt1-gradient Normal intestinal SGLT1 couples glucose entry to the inward sodium electrochemical gradient. Condition category: normal nutrient_topic: Sodium research collection; topical membership is not evidence of a direct dietary effect. plain_language: A sodium gradient helps intestinal cells take up glucose. organism: Human SGLT1 expressed in frog oocytes tissue_or_cell_type: Intestinal brush border experimental_model: Family segregation and Xenopus oocyte transport assay limitations: A genetic transporter defect is not sodium dietary deficiency; the sugar-malabsorption phenotype must not be presented as a reason to add salt. exposure: Disease-associated SGLT1 missense variant versus normal transporter evidence_span: {"source_cache": "artifacts/sodium-research/2008213.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "ba4e32dc5111895acfe9e109cf57a7e07bc3c4e07e82ad3b4f7715cfaf10af74", "start_char": 0, "end_char": 1357, "text_sha256": "ba4e32dc5111895acfe9e109cf57a7e07bc3c4e07e82ad3b4f7715cfaf10af74"} [sodium-p2008213] Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. (1991). https://pubmed.ncbi.nlm.nih.gov/2008213/ DOI: 10.1038/350354a0
Complete structured claim and evidence

Availability and dependencies

Each situation shows the normal role first, then what the sources report under a specific condition. A shortfall in the diet, a fault in the machinery, and a low blood reading are kept separate because they are not the same thing.

Hepatic Acss2 silencing reduces incorporation of fructose carbon into lipids

Condition: machinery_impairment · Experimental silencing of hepatic Acss2

Normal role: ACSS2 supplies acetyl-CoA from acetate, including microbially generated acetate.

Recorded consequence: Less bolus fructose carbon enters hepatic acetyl-CoA and fatty acids.

Scope: Component sugar mixture and gene perturbation in mice

Opening ATP-sensitive potassium channels blocks the fructose-evoked GLP-1 response

Condition: machinery_impairment · Diazoxide 340 micromolar with 10 mM fructose

Normal role: Fructose metabolism supports depolarization-associated GLP-1 release in this model.

Recorded consequence: Fructose-stimulated GLP-1 secretion is abolished.

Scope: Two-hour in vitro component-sugar and drug assay

Loss of intestinal fructose processing increases downstream exposure

Condition: machinery_impairment · Intestine-specific Khk-C deletion

Normal role: Intestinal KHK-C processes absorbed fructose before portal delivery.

Recorded consequence: More fructose reaches downstream tissues and hepatic steatosis worsens during sucrose feeding.

Scope: Sucrose-fed mice; fructose-component machinery relevant to HFCS

Khk or Fasn deletion prevents HFCS enhancement of predisposed tumor growth

Condition: machinery_impairment · Genetic loss of Khk or tumor Fasn

Normal role: Fructose metabolism and fatty-acid synthesis support the observed tumor-growth response.

Recorded consequence: HFCS no longer enhances tumor size and grade.

Scope: HFCS gavage in predisposed mice

The sources

Every document behind this chapter is preserved word for word. Open one to read it in full with its recorded conflicts marked in place.

High-Fructose Corn Syrup: mechanism of action and metabolic impact (2026-09-20)Original AI-assisted curation of twenty primary studies and official FDA composition information, with one reused canonical glucose-transport claim. Study-specific citations, negative findings and limitations retained. Not publisher full text. · unverified_draftRead preserved source
Sodium: gradients, nutrient transport, fluid regulation and loss states (2026-09-17)AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · unverified_draftRead preserved source

Recorded disagreements

Where two sources say different things, both are kept and the difference is explained. You can discuss a disagreement or propose a mechanism that might account for it.

Open questions in this collection

Questions the curators could not answer from the sources in front of them, kept here with the reason each one is still open. These are gaps in this collection, not findings or proof that no one has studied them.

Chapters are assembled from supplied drafts and curated literature summaries. Statements remain unverified against the primary studies, and the ledger is not medical advice.

Evidence, AI assistance and curation standards

High-Fructose Corn Syrup / HFCS

The mechanisms

HFCS-42 is a formulation with approximately 42% fructose in its saccharide composition.

HFCS-55 is a formulation with approximately 55% fructose in its saccharide composition.

HFCS contains free fructose rather than fructose linked to glucose in sucrose.

HFCS contains free glucose alongside fructose.

Expressed human GLUT5 selectively transported fructose, with a reported Km near 6 mM.

Adding 50 g glucose to 50 g fructose eliminated detectable breath-test malabsorption in all ten volunteers, compared with eight positive tests after fructose alone.

Fructose alone exceeded measured absorption capacity at different doses across the ten healthy volunteers.

Purified human liver ketohexokinase catalyzed the ATP-dependent phosphorylation of fructose.

Wild-type recombinant human aldolase B had catalytic activity toward fructose 1-phosphate.

The human ALDOB Arg303Trp variant had no detectable fructose-1-phosphate activity in the reported assay.

Low-dose oral fructose was approximately 90% cleared by the small intestine in the mouse tracer experiment.

Mouse intestinal tracing detected fructose-derived glucose in portal blood.

Mouse intestinal tracing detected fructose-derived lactate in portal blood.

At higher gavage doses, intestinal processing saturated and more intact fructose reached mouse portal blood and the liver.

Deleting intestinal Khk-C increased fructose spillover and hepatic lipogenesis during sucrose feeding in mice.

Dividing the same fructose dose over 45 minutes reduced hepatic lipogenesis relative to a single mouse gavage bolus.

Mouse tracer experiments identified gut-microbial acetate derived from ingested fructose.

Silencing hepatic Acss2 suppressed conversion of bolus fructose carbon into hepatic acetyl-CoA and fatty acids in mice.

Intravenous fructose acutely lowered hepatic ATP in seven healthy volunteers.

The intravenous fructose bolus acutely lowered hepatic inorganic phosphate as sugar phosphates accumulated.

After 75 g oral fructose, hepatic ATP decreased within 15 minutes and remained lower at 60 minutes in participants without MASLD.

Participants with MASLD showed a blunted ATP response to oral fructose, with only a nonsignificant early drop and recovery by 30 minutes.

HFCS beverage dose was associated with increasing postprandial triglycerides; all three sugar doses exceeded the aspartame control.

Fasting LDL cholesterol increased across increasing HFCS beverage doses in the two-week study.

Mean 24-hour urate increased with HFCS dose in the two-week study.

The HFCS group showed a 0.4 +/- 0.2 percentage-point increase in hepatic lipid from baseline; its direct contrast with aspartame was not significant.

HFCS beverages reduced Matsuda insulin sensitivity compared with aspartame in the matched-group intervention.

No measured metabolic outcome differed significantly between the HFCS and sucrose beverage groups.

HFCS and sucrose produced similar 24-hour insulin profiles with isocaloric meals.

HFCS and sucrose produced similar 24-hour circulating leptin profiles in the crossover study.

In the eight-man subset, HFCS and sucrose produced postprandial triglyceride responses comparable to pure fructose.

Fructose beverages increased basal hepatic fractional fatty-acid synthesis/secretion versus control after seven weeks.

Sucrose beverages also increased basal hepatic fractional fatty-acid synthesis/secretion; glucose did not in the same trial.

Fructose did not increase basal secretion of newly synthesized VLDL triglyceride in that trial.

Rats drinking HFCS-55 had the highest hepatic triglyceride and total lipid content among the tested solutions.

HFCS-55 exposure was associated with increased hepatic Scd1 expression in female rats.

Oral fructose stimulated GLP-1 release in healthy adults, less strongly than isocaloric glucose.

Fructose did not stimulate GIP release, whereas glucose did in the paired human challenge.

Fructose stimulated GLP-1 secretion in mouse GLUTag cells with a reported EC50 of 0.155 mM.

Diazoxide at 340 micromolar abolished fructose-stimulated GLP-1 secretion in GLUTag cells.

High-fructose feeding worsened copper status in the rat dietary experiment.

Fructose feeding prevented the duodenal Ctr1 increase otherwise observed with marginal copper deficiency in rats.

The combination of marginal copper deficiency and fructose feeding increased hepatic triglyceride and liver injury in rats.

Allopurinol lowered serum urate during the high-dose fructose intervention.

Allopurinol prevented the fructose-associated increase in 24-hour diastolic and daytime systolic/diastolic blood pressure.

Allopurinol did not reduce the HOMA insulin-resistance index during the fructose-loading trial.

PF-06835919 inhibited labeled fructose-1-phosphate formation in primary human hepatocytes.

PF-06835919 reduced fructose-associated nuclear ChREBP localization in primary rat hepatocytes.

PF-06835919 at 300 mg/day reduced liver fat relative to placebo by a reported 18.73% after six weeks.

The 75 mg/day PF-06835919 arm did not show a significant liver-fat reduction versus placebo.

Restricted daily HFCS gavage increased large and high-grade intestinal tumors in Apc-deficient mice without inducing obesity.

Khk deletion abolished HFCS enhancement of tumor growth and grade in Apc-deficient mice.

Tumor Fasn deletion abolished the growth-enhancing effect of HFCS in Apc-deficient mice.

An acute HFCS bolus lowered ATP in Apc-deficient intestinal tumors; the change was absent with Khk deletion.

Normal intestinal SGLT1 couples glucose entry to the inward sodium electrochemical gradient.

Availability and dependencies

The sources

Recorded disagreements

Open questions in this collection